Arachnoiditis: Leveraging crowdsourcing and AI in a cross-sectional study of 1,105 cases to improve identification, understanding, and treatment

Lori Verton BSc RCPT[1], Noga Minsky MD[2,3], Eran Dotan MD[2,4], Roni Sharon MD[2,5], Megan Black BAppSci MPH[1], Patricia Gomes-Lourens MD[1], Deepmala Rana Bhat BPH MPH[1,6], Shristi Sharma BSN MSc[1,6], Ishna Singh MD[1], Linda Bavisotto MD FACP[1*]

[1] Arachnoiditis and Chronic Meningitis Collaborative Research Network (ACMCRN), London, Ontario
Canada

[2] Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel

[3] Division of Endocrinology, Diabetes and Metabolism, Sheba Medical Center, Ramat Gan, Israel

[4] StuffThatWorks Ltd, Tel Aviv, Israel

[5] Department of Neurology, Sheba Medical Center, Ramat Gan, Israel

[6] Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada

***Corresponding author:**

Email: bavisotto@acmcrn.org (LB)

ORCID 0000-0002-9620-3835

Abstract

Introduction

Arachnoiditis, a painful and potentially disabling neurological condition, results from persistent inflammation of the spinal cord pia-arachnoid membranes following injury. While considered rare, the condition is underdiagnosed. Research on symptomatology, diagnosis, and treatments is scarce, hindering clinical management. Artificial intelligence (AI) offers promising opportunities for rare diseases, enabling large-scale pattern identification. This study used traditional research methods and AI technology to characterize the clinical presentation, comorbidities, aggravating factors, and treatments for arachnoiditis.

Methods

An international cross-sectional survey was conducted online using StuffThatWorks® (STW), an AI-based platform for people with chronic diseases. Multiple choice and free text responses were assessed both quantitatively and qualitatively. Novel AI/machine learning algorithms were used to further analyze the data, including the STW cross-condition score (higher scores more indicative of arachnoiditis) and the STW treatment efficacy model generating effectiveness and detriment estimates, with binomial proportion 90% confidence intervals.

Results

Of 1250 respondents, 1105 reporting a physician-confirmed diagnosis were included. Participants were predominantly USA-based (71.4%), female (75.9%) and ≥46 years old (73.1%). Of 712 symptoms grouped into eight categories, eighteen were more indicative of arachnoiditis (by cross-condition score). The most frequent symptoms were lower back pain

(43.5%), leg pain (41.6%) and back pain (39.1%). Prolonged sitting (62.5%) and prolonged standing (58.3%) were the most common aggravating factors. Comorbidities were led by degenerative disc disease (32.3%), spinal stenosis (25.3%) and fibromyalgia (25.0%). Most frequently used treatments were gabapentin (37.9%), physiotherapy (30.1%) and pregabalin (26.5%). Treatments with highest patient-rated effectiveness (by STW model, 90% CI) were low-dose naltrexone (28.1%, CI 20.0-37.0), ketamine infusion (24.8%, CI 16.9-33.4) and fentanyl (21.1%, CI 14.7-28.1). Epidural corticosteroid injections showed highest detriment (38.5%, CI 28.0-45.9).

Conclusion

As the largest observational study of arachnoiditis to date, made possible with novel methodological approaches, this work offers new insights with potential to improve diagnosis and management.

Introduction

Arachnoiditis is a painful, potentially debilitating neurological condition resulting from persistent inflammation of the spinal cord pia-arachnoid membranes (leptomeninges) and the subarachnoid space between them [1–3]. A cascade of neuroinflammation in response to injury—a normally healthy mechanism but persistent or excessive in arachnoiditis—results in early spinal nerve swelling and leads to thickening and clumping of spinal nerve roots [1,3,4]. The process can be focal or diffuse, and over time becomes compounded by the development of permanent scarring and adhesions, entrapping nerves and disrupting the normal flow of cerebrospinal fluid (CSF) in the subarachnoid space. Fibrosis and CSF flow disturbances can lead to spinal cord tethering, syrinx formation, myelomalacia, spinal cord atrophy, and myelopathic symptoms [1,2,5–9].

Arachnoiditis manifests with a wide spectrum of clinical presentations, and the course of the condition is highly variable [10]. Advanced stage adhesive arachnoiditis is commonly characterized by intractable neuropathic pain, significant mobility issues and myriad neurologic impairments [1,9,11]. Complications can extend to genitourinary, gastrointestinal and autonomic nervous systems [12,13]. Together, these disease expressions can lead to significant morbidity, disability and shortened lifespan [3,13,14]. Considered a rare condition, often misdiagnosed and overlooked, much remains unknown about the epidemiology and natural history of arachnoiditis, or the efficacy of interventions [1,15].

Clinical symptoms of arachnoiditis can appear acutely within hours or days of an inciting event, or develop gradually over months to years, or even decades, often leading to

delayed diagnosis or misdiagnosis [1,9,11,16]. The condition may be triggered by a variety of factors, primarily involving physical damage or chemical injury to the spinal cord, or by infection of the spinal meninges. Injury may occur because of trauma to the spinal cord, subarachnoid hemorrhage or other introduction of blood into the CSF, edema, or post-surgical or post-procedural inflammation [1,5,17,18]. Exposure of the meninges and CSF to a variety of chemicals has also been documented to cause arachnoiditis, with offending agents including intrathecal chemotherapy, corticosteroids, oil-based radiographic contrast agents, detergent solvents, contaminants, and preservatives such as polyethylene glycol, to name just a few [1,19]. Infectious meningitis can be caused by fungal, bacterial, viral, or parasitic pathogens [1,20]. Chronic meningitis, or aseptic arachnoiditis, are terms sometimes used to refer to inflammation without evidence for a causal infectious pathogen. The condition can also be triggered by autoimmunity, for example as an adverse immune event due to immune checkpoint inhibitor therapy of various malignancies [21]. In addition, idiopathic cases are not uncommon [1,22].

Whereas arachnoiditis arising as a late complication of meningeal infection may favor cervical and thoracic spine distribution [1], where the disease tends to be more progressive [2], the current predominance of lumbar arachnoiditis appears to be related to an increasing frequency of invasive lumbar spinal interventions, including various surgical techniques as well as epidural anesthesia and injections. Iodinated oil-based myelographic contrast imaging agents such as iophendylate, administered via lumbar puncture into the subarachnoid space, have been associated with the development of numerous cases of iatrogenic arachnoiditis [1,4,14,19], and these agents were subsequently removed from the market. Fungal meningitis and arachnoiditis were documented in a number of clustered

cases arising from contamination of methylprednisolone in epidural injections in 2012 [23–25] and of spinal anesthesia in 2023 [26]. An updated American practice advisory was issued in 2017 on the prevention, diagnosis and management of infectious complications associated with neuraxial techniques [27].

It is important to emphasize that most individuals with the aforementioned exposures do not develop arachnoiditis. Some individuals may have underlying risk factors that predispose them. There appears to be an association with pre-existing anatomic spinal abnormalities as well as age-related degeneration, particularly in lumbar arachnoiditis [3,7,14,28,29]. These conditions also lead to increased invasive spinal interventions, with multiple spinal interventions (of any kind) or traumatic procedures being more closely associated with the development of arachnoiditis [1,4,30]. There may be an increased risk in persons with auto-immune or systemic inflammatory conditions, such as autoimmune vasculitis, ankylosing spondylitis, mixed connective tissue disease or rheumatoid arthritis [1,31–33]. Additionally, a potential association with genetic connective tissue disorders, such as Ehlers-Danlos Syndrome (EDS), has been described in a limited number of studies [34,35]. Rare cases of familial arachnoiditis with syringomyelia have been documented [36], suggesting the possibility of an unidentified genetic susceptibility component in these individuals. A potential association between arachnoiditis and Tarlov (perineural) cysts has also been reported [34,37,38]. Various authors suggest that in many cases arachnoiditis is likely to result from a combination of risk factors or inciting events [4,14,34,39].

Diagnosis of arachnoiditis is based on history, individual clinical findings and MRI features. MRI is the preferred imaging modality, although CT myelography may be used

134 when MRI is contraindicated [29]. Over the past 50 years, several staging classification
135 systems for arachnoiditis have been proposed and modified based on symptoms,
136 histopathology, morphology and patterns of radiographic progression [14,40,41]. Expanding
137 upon the pathognomonic radiological patterns first established in the 1980s [40,42], recent
138 diagnostic studies of advanced stage adhesive arachnoiditis show that MRI findings may
139 include abnormal clumping and irregular distribution of spinal nerve roots, abnormal nerve
140 root contours, nerve root enhancement, synechia, loculated and typically dorsal arachnoid
141 cysts, as well as signs of CSF flow disturbance [10,28,29,43]. While radiological staging
142 classifications have focused primarily on lumbar arachnoiditis, disease occurring in other
143 spinal areas and the brain may be even more difficult to characterize on MRI [44–46].
144
145 Several limitations complicate the diagnosis of arachnoiditis in clinical practice.
146 Imaging findings are highly variable [29], and correlate poorly with symptom severity
147 [43,47]. In the cervicothoracic spine, neurosurgical observations show that MRI often
148 incompletely visualizes the extent of chronic arachnoiditis, especially focal arachnoiditis
149 [44,45]. In the lumbar spine, endoscopic surgery suggests that in some cases MRI may fail
150 to identify the condition at all [37,48,49], leading some authors to propose that mild
151 arachnoiditis may be overlooked in patients with unexplained lumbar radiculopathy
152 symptoms but normal MRI studies [50]. Adding to these diagnostic challenges, acute
153 iatrogenic lumbar arachnoiditis may initially present with minimal MRI findings – early
154 imaging may show only nerve root enhancement before other characteristic features
155 develop, or may appear entirely normal [51–55].
156

To address these limitations, several diagnostic methods have recently been described. In the cervicothoracic spine, specialized MRI sequences and morphometric analyses for improving visualization or inferring diagnosis have been employed [44,56–59]. In the lumbar spine, proposed approaches include prone MRI to detect failure of the nerve roots to migrate ventrally with gravity due to nerve root tethering [60], and morphometric analysis to assess for mildly enlarged thecal sac dimensions [22,48,61,62]. MR neurography of the lumbosacral plexus has also detected arachnoiditis not otherwise apparent on standard MRI [63]. In the absence of a definitive diagnostic test and reflecting a lack of clear consensus in the field, Epstein and Agulnick [47] have suggested that a characteristic constellation of symptoms alone should suffice to make the clinical diagnosis of lumbar arachnoiditis, without requirement for radiographic confirmation.

Early and accurate diagnosis is important, as some therapeutic options for arachnoiditis may be more effective when given in the initial stages of neuroinflammation. When diagnosis is not definitive, however, early intervention may be delayed to avoid possible complications. In those with recent onset early stage arachnoiditis, a variety of anti-inflammatory, fibrinolytic, and immune-suppressive therapies have been empirically offered in an attempt to arrest or slow the process of fibrosis and neuropathic progression [1,12,53,64,65]. According to several recent reports, high-dose corticosteroids administered in the earliest stages of acute arachnoiditis, often iatrogenic cases, have led to recovery in the short term [52,53,64,66,67]. However, the evidence is mixed, not all patients respond or respond completely, and some patients recover spontaneously [1,52]. Most reports are missing sufficient details. Further studies with standardized treatments and long-term outcome assessments are needed as a critical research priority.

In patients experiencing progressive neurological deterioration, surgical intervention such as detethering procedures, adhesiolysis, cyst fenestration and decompression of intradural arachnoid cyst or syrinx with or without shunting may be indicated [1,2,5,44,62,68,69], however these procedures carry inherent risks of potential further compromise in neurological function as well as development of post-operative inflammation and scarring, which may lead to arachnoiditis recurrence. The primary surgical objectives are to restore or improve CSF flow at sites of obstruction and to alleviate spinal cord compression.

The majority of contemporary literature on surgical management report on cases of thoracic and cervical arachnoiditis, although some have included lumbosacral cases [5]. Favorable surgical outcomes have been reported, particularly early in disease prior to significant spinal cord damage [2], although follow-up is often short and information incomplete. There is relatively consistent evidence indicating that patients with focal spinal involvement of arachnoiditis (limited to several vertebral segments) have better surgical and neurologic outcomes post-operatively than those with extensive/diffuse spinal involvement [2,44]. Minimally invasive neurosurgical approaches such as percutaneous intrathecal endoscopy continue to evolve [37,48,49,62,70,71] and are sometimes combined with limited laminectomy procedures [2,69] to allow direct visual assessment and safe removal of adhesions in spinal segments adjacent to the laminectomy margins, extending the range of the surgeon’s reach beyond what would be possible with conventional laminectomy.

For patients who are not surgical candidates, management focuses on symptom-directed supportive care and comprehensive chronic pain management [72,73]. Current pharmacological and non-surgical interventions have variable results, typically providing modest symptom relief at best, often with limited long-term benefit [1,3,11,12].

Substantial hurdles have impeded studies regarding the diagnosis, natural history and treatments for arachnoiditis. One challenge is the lack of standardized terminology for arachnoiditis and its varying degrees of severity, with Palackdharry et al. [1] identifying up to 63 different terms used across specialties. Determining clinically significant pathology also remains unclear [74,75]. In addition, because arachnoiditis spans multiple specialties without fitting neatly within one, research is fragmented [74]. Consequently, limited literature exists regarding pathophysiology, symptomatology and accurate diagnosis, rendering correct identification of the condition difficult. Inaccurate diagnosis may be common, as reflected by poor inter-rater reliability (kappa score 0.05) in a 2021 study where five specialized radiologists reviewed MRI images from 96 patients with hallmark criteria of the disease [28]. The inconsistent lag times between insult and clinical presentation may further contribute to delayed and missed diagnosis [10,61]. Chronicity of symptoms and the presence of comorbidities may also complicate the clinical picture.

In recent years, the advancement of bio-registries, online patient advocacy groups, and big data are beginning to overcome financial and logistical hurdles to understanding and treating rare diseases. In addition, there has been increasing interest in arachnoiditis, with the number of publications growing [1,76]. Following a collaborative research network model in which patient-led initiatives have successfully accelerated research into rare

228 diseases [77–79], we sought to determine if these developments could be employed in the
229 pursuit of defining more accurate diagnostic criteria, identifying more effective personalized
230 treatment options, assessing patient-reported outcomes, and bringing more attention to the
231 condition. This study is an application of these approaches, specifically aiming to
232 characterize symptoms, aggravating factors, comorbidities and treatments among a large
233 cohort of individuals living with arachnoiditis. This work serves as a prelude to the creation
234 of an international arachnoiditis patient registry and development of further studies.

235 Methods

236 Patient recruitment

237 The Arachnoiditis and Chronic Meningitis Collaborative Research Network
238 (ACMCRN) [80] implemented a structured international cross-sectional health-related
239 survey among individuals living with arachnoiditis. Recruitment was via a combination of
240 targeted social media campaigns and word-of-mouth strategies, or snowball sampling,
241 recommended as a practical form of study recruitment for rare diseases [81]. To be included
242 in the current study, participants had to indicate that arachnoiditis was diagnosed by a
243 physician. Data was collected between July 2020 and December 2022.

244 Study tools

245 This study utilized the StuffThatWorks platform [82], a free commercial crowd-
246 sourcing site that provides an online venue for people living with chronic conditions to share
247 personal experiences within condition-specific groups, termed “communities”. The platform
248 transforms each group’s collective experience into an organized knowledge database,
249 enabling members to self-educate. With 2.9 million members at the time of writing, across

1,261 conditions, individuals share information about their disease experiences, symptoms and treatments. Natural language processing and machine learning algorithms analyze entries to generate insights about age of onset, symptoms, aggravating factors and treatments. Once several hundred responses are collected, the algorithm begins to rank different treatments by effectiveness, and with thousands of responses it predicts the most effective treatments based on user assessments.

Participation in the online survey is entirely voluntary, confidential and anonymous. As a precondition for joining the STW survey platform, participants are asked to provide informed consent for the inclusion of their anonymized data in studies. With the exception of several essential questions, participants are free to disclose only information they want to share and to opt out of the platform and data sharing at any time. Data collected by STW are stored in a de-identified manner and a designated number is assigned to each user. STW obtained local institutional review board approval for the platform and English-language survey (Sheba Medical Center protocol #7356-20). For the purposes of the current study, survey data from the platform was provided to the authors in a de-identified, aggregate format, with age categories, rather than precise age. No data was provided that could identify or be linked to any participant.

Participants provided current age, sex at birth, age at symptom onset, and were asked to describe symptoms, aggravating factors, comorbid conditions, and all previously attempted arachnoiditis treatments in detail (including medicines, supplements, procedures, protocols, dietary changes, alternative or complementary therapies, classes); see S1 File for survey questions. Several survey questions used open-text fields so as not to limit

responses to a predetermined list. This exploratory approach necessitated that compiled results include both qualitative and quantitative data.

Data analysis

Responses to open-ended questions were coded into structured entities using STW's proprietary "normalization tool" as a component of natural language processing. For example, for a question regarding main symptoms, the answer "leg weakness and tingling" would be normalized into two different "symptom" entities: "leg weakness" and "leg tingling". Numbers for each response were given out of the total number of valid responses (n), after exclusion of patients who did not answer the question and responses that were not normalized successfully by the normalization tool.

Quantitative data is shown as frequencies and percentages. Quantitative results also include an innovative algorithm unique to STW, the proprietary "STW cross-condition score". This score uses AI-based models to measure how specific an entity or response is to one disease community when compared to all other communities on the platform. The scale ranges from 1-10, with a score of 10 for an entity (such as a symptom, aggravating factor or comorbidity) which is very commonly reported in one community (e.g., arachnoiditis) but is rarely reported in others. Thus, higher scores indicate higher specificity for the condition of interest. A cross-condition score > 6 is highly indicative of a given condition; a score between 3-5 is moderately indicative for the condition; and a score < 3 is a weak indicator for the condition. Novel research approaches are increasingly recognized as important for advancing understanding of rare diseases [83]. Given that results from other STW analytical models have demonstrated consistency with traditional research

297 findings [84,85] the authors included the cross-condition score data alongside standard
298 research results.
299
300 To evaluate treatment effectiveness, alongside the primary data, a proprietary STW
301 treatment efficacy model was used [84–86]. Treatment effectiveness was expressed as an
302 estimated ratio of how many respondents rated a treatment as effective, out of the total
303 number of reports of this treatment (i.e. number of effective reports/numbers of tried
304 reports), while accounting for the level of certainty in the estimate based on the overall
305 number of reports for each treatment. A hierarchical Bayesian calculation generates a
306 binomial proportion confidence interval around the estimated proportion. To prevent over-
307 evaluation of the effectiveness of rarely used treatments, the model accounts for the
308 number of reports on each treatment, such that treatments with many reports are given
309 greater weighting than those with few reports. The model does not distinguish between
310 treatments which were taken for specific symptoms but rather assumes that all treatments
311 are targeting the condition as a whole. The output is expressed as a percentage together
312 with a 90% confidence interval.
313
314 Where a large volume of findings was captured from open-ended questions, results
315 are presented according to a combination of both quantitative and qualitative methods.
316 Qualitative analysis involved content analysis and categorization [87] of like responses for
317 symptoms and aggravating factors, where ≥ 1% of the total study population entered the
318 same response. This analysis enabled a detailed exploration of the full breadth of
319 responses. In the absence of substantial prior research, qualitative methods are critical for
320 generating insight, and, in the context of rare diseases, mixed method approaches are

321 valued for incorporating lived experiences as meaningful input [88,89]. Although three
322 authors (MB, LB, IS) did the content analysis and categorization, all authors agreed upon
323 the final categorization of qualitative data.
324
325 Feedback on aggregate results and insights from the survey was offered by
326 ACMCRN to the arachnoiditis online support groups community in a series of publicized
327 online webinars at the conclusion of the project.

328 Results

329 Demographics

330 Of the 1250 self-identified individuals living with arachnoiditis who responded to the
331 survey, 1105 (88.4%) affirmed that their diagnosis of arachnoiditis had been confirmed by a
332 doctor and their results alone are included in the following analysis.
333
334 The study cohort was international, with a majority of participants (71.4%) from the
335 United States. Approximately three quarters (75.9%) of respondents were female. White or
336 European ethnicities were predominant among survey participants, while black or African
337 American, Asian, and Hispanic ethnicities were relatively underrepresented. Specific
338 demographic characteristics of the study participants are summarized in Table 1.
339

340 **Table 1. Demographic characteristics (n = 1105)**

Characteristic	n	%
Sex (at birth)		
Female	839	75.9
Male	266	24.1
Country		
United States	789	71.4
United Kingdom	77	7.0
Canada	50	4.5
Australia	31	2.8
Germany	12	1.1
South Africa	7	0.6
Others	139	12.6
Age at time of survey		
0-18 years	3	0.3
19-30 years	43	3.9
31-45 years	252	22.8
46-65 years	615	55.7
66+ years	192	17.4
Age at time of symptom onset [a]		
0-18 years	26	2.5
19-30 years	133	13.0
31-45 years	389	38.1
46-65 years	408	39.9
66+ years	66	6.5
Ethnicity [b]		
White	943	89.0
European	207	19.5
American Indian or Alaska native	45	4.2
Hispanic or Latino	45	4.2
Asian	20	1.9
Black or African American	16	1.5
Arab or Middle East	9	0.8
Body Build [c]		
Significantly underweight	25	2.2
Moderately underweight	78	7.1
Average weight	441	39.9
Moderately overweight	452	40.9
Significantly overweight	109	9.9

341 **n, number.**
342 **[a] Not all participants reported age at initial onset (n = 1022).**
343 **[b] Totals for ethnicity are greater than 1105 as participants were able to select multiple responses for**
344 **ethnicity, as applicable.**
345 **[c] Body build was self-reported by participants.**
346

347 Participant age at the time of taking the survey and at appearance of initial
348 symptoms are presented in Fig 1. The majority of respondents at the time of the survey
349 (73.1%) were ≥ 46 years old. At the time of initial symptom onset there is a proportional
350 shift to the younger ages, with more than half (53.6%) ≤ 45 years.
351
352 **Fig 1. Comparison of age distribution at time of survey and at onset of symptoms (n = 1105)**



353
354 **n, number.**
355 *** Not all participants reported age at symptom onset (n = 1022)**
356

357 # Assessment of symptoms

358 Participants were asked to list their symptoms in order of severity. Almost all
359 participants (99.6%, n = 1101) responded to this question, including 74 respondents who
360 listed no specific symptoms. A total of 712 specific symptoms were described. Fig 2
361 displays the 20 most frequently reported symptoms and their percentages, with color
362 coding to denote symptoms with STW cross-condition scores > 6 (most indicative for
363 arachnoiditis).
364

365 **Fig 2. Most frequent symptoms (n = 1101)**



366

367 **n, number; STW, StuffThatWorks.**
368 **ᵃ STW cross-condition score (scale 1-10): A score > 6 is highly indicative for arachnoiditis, a score**
369 **between 3-5 has a medium degree of indication, and a score < 3 has a low indication (see Methods);**
370 **solid bars represent scores > 6.**
371

372

373 Given the large volume of symptoms described (n = 712), the 10% most frequently
374 cited (n = 71) were categorized into groups of like symptoms using content analysis
375 methodology. This produced 8 main symptom categories: pain; symptoms of motor nerve
376 damage or irritation; altered sensation; symptoms experienced in the feet; bladder or bowel
377 issues; head and neck symptoms; difficulty with daily activities; and “other” (autonomic,
378 gastrointestinal, endocrine, autoimmune, heat or temperature sensation, and not otherwise
379 categorized). Analysis of the additional 67 symptoms reported by ≥ 1% of the total study

population (i.e. ≥ 11 people) did not yield any further distinct symptom categories beyond those previously identified.

Table 2 presents the symptoms in each category and corresponding percentages. STW cross-condition scores (also shown for each symptom), revealed a hierarchy of symptoms highly indicative of arachnoiditis (scores > 6), with decreasing significance as follows: lower back pain, legs pain, formication, electric shock feeling, burning sensation in feet, weakness in legs, numbness in feet, bladder issues, numbness in legs, burning sensation in legs, numbness, back pain, muscle spasms, foot pain, burning sensation, buttocks pain, shooting leg pain, and tingling sensation. See Table S1 for a full list of symptoms reported by ≥ 1% of the study population ordered by frequency (n, %, score).

Table 2: Main symptoms by category (n = 1101)

Categories	Symptoms % (STW cross-condition score [a])					
Pain						
Spinal pain	Lower back pain	43.5%	**(7.21)**	Back pain	39.1%	**(6.86)**
	Spine pain	3.3%	(5.04)	Lumbar region pain	3.1%	(5.65)
	Pain across sacrum	2.9%	(4.99)			
Referred pain	Legs pain	41.6%	**(7.12)**	Burning sensation in legs	10.8%	**(7.00)**
	Hip pain	9.6%	(5.59)	Buttocks pain	8.7%	**(6.24)**
	Sciatica	5.9%	(5.44)	Shooting leg pain / radiating pain down leg	4.6%	**(6.17)**
	Nerve pain in legs	4.5%	(5.25)	Radiating pain	4.2%	(5.00)
	Right leg pain	3.5%	(5.18)	Left leg pain	2.9%	(5.24)
	Groin pain	2.9%	(3.80)			
Pain quality	Burning sensation	20.7%	**(6.34)**	Electric shock feeling	18.4%	**(7.08)**
	Sharp / stabbing pain	13.0%	(5.93)	Nerve pain	8.4%	(5.41)
	Burning pain	7.6%	(5.93)	Shooting pains	6.7%	(5.61)
	Stinging	4.9%	(5.21)	Severe pain	4.9%	(3.08)
	Crippling / extreme pain	3.7%	(5.11)			
Pain other	Pain / chronic pain	27.0%	(3.70)	Widespread pain / body aches	3.5%	(2.73)
Motor nerve damage or irritation	Muscle spasms	19.3%	**(6.64)**	Weakness in legs	18.3%	**(7.01)**
	Weakness	12.2%	(5.01)	Foot drop	5.7%	(5.54)
	Neuropathy	5.5%	(5.38)	Leg cramps	5.1%	(5.23)
	Twitching	4.8%	(5.08)	Cramping	4.6%	(3.14)
	Spasms	3.7%	(3.96)	Leg/s spasms	3.4%	(4.88)
Altered sensation	Numbness	30.5%	**(6.96)**	Tingling sensation	18.0%	**(6.05)**
	Numbness in legs	16.4%	**(7.00)**	Formication (feeling of something crawling on you)	15.2%	**(7.09)**
	Tingling legs	7.9%	(5.50)	Pins and needles	5.4%	(4.79)
	Lower leg numbness	4.3%	(4.74)	Water dripping sensation	3.8%	(5.63)
Symptoms in feet	Numbness in feet	17.2%	**(7.01)**	Foot pain	16.6%	**(6.52)**
	Burning sensation in feet	14.4%	**(7.04)**	Tingling feet	6.0%	(5.06)
Bladder or bowel symptoms	Bladder issues (unspecified)	11.9%	**(7.01)**	Incontinence	10.3%	(5.69)
	Bowel issues (unspecified)	6.6%	(5.20)	Fecal incontinence	4.2%	(5.14)
Head and neck symptoms	Headaches	22.3%	(4.54)	Blurred vision	8.0%	(5.21)
	Balance issues / loss of balance	7.5%	(4.83)	Neck pain	6.6%	(4.37)
	Migraines	6.4%	(3.32)	Tinnitus	6.2%	(4.96)
	Dizziness / severe dizziness	4.4%	(2.32)	Brain fog	3.3%	(2.09)
Difficulty with daily activities	Mobility issues / difficulty walking	18.0%	(5.48)	Difficulty standing	9.4%	(5.82)
	Difficulty sitting	7.6%	(5.61)	Pain sitting	3.8%	(5.44)
	Unable to walk / stand	3.0%	(3.72)			
Other	Fatigue	10.9%	(1.95)	Insomnia	4.8%	(2.54)
	Sweating / overheating	4.5%	(3.55)	Depression / feeling depressed	3.9%	(2.04)
	Nausea	3.1%	(1.72)			

[a] STW (StuffThatWorks) cross-condition score (scale 1-10): A score > 6 is highly indicative for arachnoiditis, a score between 3-5 has a medium degree of indication, and a score < 3 has a low indication (see Methods); scores > 6 are shown in bold.

Earliest presenting symptoms

Participants were asked to recall whether, prior to diagnosis or early in the condition, there were any symptoms or warning signs that worried them or made them feel something

was not right. The majority of participants (92.2%, n = 1019) endorsed early symptoms, reporting 418 symptoms, similar in character to the general arachnoiditis symptoms participants had listed. Pain and altered sensation were predominant among the most common reported early symptoms (14/20 symptoms). An absence of early symptoms was indicated by 8.8% of respondents. The frequency, percent and STW cross-condition score for the 20 most common early symptoms are presented in Table 3. See Table S2 for a full list of early symptoms reported by ≥ 1% of the total study population ordered by frequency (n, %, score).

Table 3. Most frequent early symptoms (n = 1019)

Early symptom	n	%	STW cross-condition score [a]
Pain / chronic pain	172	16.8	5.40
Back pain	110	10.8	**7.03**
None	90	8.8	-
Legs pain	73	7.1	**7.00**
Lower back pain	51	5.0	**7.00**
Mobility issues / difficulty walking	48	4.7	5.17
Numbness	47	4.6	**6.02**
Numbness in legs	44	4.3	**6.72**
Constant pain	41	4.0	5.26
Severe pain	41	4.0	5.07
Burning sensation	39	3.8	5.79
Weakness in legs / jelly legs	36	3.5	**6.07**
Numbness in feet	34	3.3	**6.16**
Deterioration of health / condition / worsening of symptoms	31	3.0	2.82
Electrical shock feeling	30	2.9	**6.10**
Burning sensation in legs	28	2.7	5.92
Surgery induced condition	28	2.7	5.62
Crippling / extreme pain	27	2.6	5.58
Headaches	27	2.6	3.67
Tingling sensation	26	2.5	5.12

n, number; STW, StuffThatWorks.

[a] STW cross-condition score (scale 1-10): A score > 6 is highly indicative for arachnoiditis, a score between 3-5 has a medium degree of indication, and a score < 3 has a low indication (see Methods); scores > 6 are shown in bold.

Assessment of aggravating factors

Factors which exacerbated their condition were reported by 95.0% of respondents (n = 1050), comprising 276 different aggravating factors. The 20 most frequently reported aggravating factors are presented in Fig 3. “Sitting or sitting too long” and “standing or standing too long” were the most common aggravating factors, reported by 62.5% and 58.3% of respondents, respectively, and carried the highest cross-condition scores for aggravating factors at 7.70 and 7.59, respectively.

Fig 3. Most common aggravating factors (n = 1050)



n, number; STW, StuffThatWorks.
ᵃ STW cross-condition score (scale 1-10): A score > 6 is highly indicative for arachnoiditis, a score between 3-5 has a medium degree of indication, and a score < 3 has a low indication (see Methods); solid bars represent scores > 6.

Analysis revealed 62 exacerbating factors reported by ≥ 1% of participants, stratified into eight discrete categories: positional factors (sitting, standing, or lying down); specific movements or activities; physical exertion intensity; weather or temperature variables; physical or mental health parameters; medical treatment or non-treatment; inactivity; and miscellaneous variables. Table 4 presents these factors by category, including their frequency and STW cross-condition scores. See Table S3 for a full list of aggravating factors reported by ≥ 1% of the study population ordered by frequency (n, %, score).

Table 4. Aggravating factors by category (n = 1050)

Categories	Subcategory	Aggravating factors % (STW cross-condition score [a])					
Specific positions	Sitting	Sitting or sitting too long	62.5%	**(7.70)**	Car rides / long car rides	3.8%	(5.04)
		Driving	3.8%	(5.02)	Sitting upright	1.6%	(3.32)
	Standing	Standing or standing too long	58.3%	**(7.59)**	Standing still	3.2%	(5.39)
	Lying down	Laying down	7.5%	**(6.16)**	Lying down for long	3.8%	(5.43)
		Lying on back	2.4%	(4.40)	Sleep	1.1%	(1.56)
	Positions – general	Being in one position too long	4.5%	**(6.14)**	Certain positions	1.2%	(2.02)
Specific movements or activities	Walking	Walking	30.6%	**(7.17)**			
	Bending, twisting or stretching	Bending over	22.7%	**(7.29)**	Twisting	5.8%	**(6.33)**
		Stretching	2.4%	(4.60)	Reaching up	1.4%	(3.81)
	Lifting	Lifting	14.2%	**(7.10)**	Heavy lifting	3.5%	(4.67)
		Carrying heavy things	1.1%	(1.85)			
	Transitional movements	Standing up	5.4%	**(6.54)**	Squatting	2.9%	(5.38)
		Stair climbing / going down stairs	1.5%	(2.61)			
	General / non-specific	Everything / life	3.2%	(3.57)	Certain activities	1.7%	(1.93)
		Housework	1.5%	(3.36)	Cleaning	1.3%	(2.62)
		Gardening	1.0%	(2.05)			
Physical exertion intensity		Walking too much	15.5%	**(7.08)**	Activity / too much activity	12.7%	**(6.24)**
		Excessive movement	10.2%	(5.76)	Physical exertion	10.1%	(4.73)
		Overdoing	7.1%	(5.61)	Physical activity	5.1%	(4.80)
		Exercise	4.1%	(2.09)	Running	2.0%	(2.95)
Weather or temperature		Cold weather	7.5%	(3.35)	Temperature / weather (unspecified)	4.8%	(3.91)
		Weather changes	3.4%	(4.18)	Barometric pressure changes	3.0%	(4.69)
		Heat	2.4%	(1.65)	Humidity	2.2%	(2.40)
		Hot weather	1.5%	(1.96)	Wet weather	1.2%	(1.85)
Physical or mental health parameters		Stress	17.3%	(1.62)	Lack of sleep	3.2%	(1.49)
		Fatigue	2.6%	(1.70)	Pain	2.0%	(2.86)
		Poor sleep	1.2%	(1.83)	Sleep	1.1%	(1.56)
		Falling	1.1%	(2.42)	Anxiety / feeling anxious	1.0%	(1.22)
Medical treatment or non-treatment		Medication (unspecified)	11.8%	(1.33)	Not adhering to treatment	3.4%	(2.01)
		Surgery	1.6%	(2.84)	Lack of treatment	1.1%	(1.67)
Inactivity		Lack of movement	2.8%	(3.54)	Inactivity	2.5%	(2.43)
		Lack of exercise	1.2%	(1.35)			
Miscellaneous		Sugar / too much sugar	2.7%	(1.61)	Menstrual cycle (period)	1.1%	(1.43)
		Alcohol / drinking too much	1.0%	(1.11)	Poor diet	1.0%	(1.23)

[a] STW (StuffThatWorks) cross-condition score (scale 1-10): A score > 6 is highly indicative for arachnoiditis, a score between 3-5 has a medium degree of indication, and a score < 3 has a low indication (see Methods); scores > 6 are shown in bold.

Assessment of comorbid conditions

Participants were asked to list all diagnosed comorbid medical conditions, with 830 (72.2%) respondents reporting at least one such condition. The 20 most common conditions are shown in Table 5 along with their frequency, % and STW cross-condition score. Eight comorbidities were spine-related in origin, seven of which yielded cross-condition scores highly indicative for arachnoiditis.

Table 5. Most common comorbidities (n = 830)

Comorbidity	n	%	STW cross-condition score [a]
Degenerative Disc Disease (DDD)	268	32.3	**7.13**
Spinal stenosis	210	25.3	**7.33**
Fibromyalgia	207	25.0	3.82
Hypertension	112	13.5	2.10
Osteoarthritis	103	12.4	4.97
Arthritis (unspecified)	99	11.9	5.04
Cauda equina syndrome	91	11.0	**7.52**
Scoliosis	85	10.3	5.86
Clinical depression	84	10.1	1.24
Migraine	83	10.0	2.03
Failed back surgery syndrome (FBSS)	82	9.9	**7.43**
Tarlov cysts	81	9.8	**7.39**
Herniated disc	70	8.4	**7.02**
Hypothyroidism	69	8.3	1.72
Anxiety / generalized anxiety disorder (GAD)	68	8.2	1.15
Ehlers Danlos Syndrome (EDS)	66	8.0	4.09
Diabetes mellitus	56	6.8	2.55
Bulging discs	53	6.4	**7.00**
Complex regional pain syndrome	50	6.0	**6.43**
Rheumatoid arthritis	47	5.7	2.93

n, number; STW, StuffThatWorks.

[a] STW cross-condition score (scale 1-10): A score > 6 is highly indicative for arachnoiditis, a score between 3-5 has a medium degree of indication, and a score < 3 has a low indication (see Methods); scores > 6 is shown in bold.

Survey of treatments

The 30 treatments most frequently tried by the 982 participants (88.9%) who responded to this question are shown in Table 6, ordered by self-rated effectiveness (STW estimated ratio). The 90% confidence intervals for rates of effectiveness are generally quite broad, reflecting the relatively small numbers of participants who rated individual treatments as effective.

Among the treatments in Table 6, it can be seen that the most frequently tried treatments are not the same as those self-rated as most effective. The most frequently tried treatments (listed by ≥ 20% of respondents) include gabapentin (37.9%), physiotherapy (30.1%), pregabalin (26.5%), and oxycodone (23.5%). In contrast, the treatments with the highest rated effectiveness (≥ 20% estimated ratios) include low-dose naltrexone (28% effective, tried by only 6.8%), ketamine infusion (24.8%), fentanyl (21.1%), and oxycodone (20.9%).

471 **Table 6. Most frequently tried treatments, ranked by self-rated effectiveness (n = 982)**

Treatment tried	Total [a] n (%)	Self-rated as effective [b]		
		n	STW estimated ratio [c]	90% CI
Naltrexone hydrochloride (low dose naltrexone)	67 (6.8%)	20	28.1%	20.0%-37.0%
Ketamine hydrochloride (ketamine infusions)	65 (6.6%)	17	24.8%	16.9%-33.4%
Fentanyl (patch and other routes)	92 (9.4%)	20	21.1%	14.7%-28.1%
Oxycodone hydrochloride	231 (23.5%)	49	20.9%	16.8%-25.4%
Pain relief medication (unspecified)	97 (9.9%)	20	20.1%	14.0%-26.8%
Morphine sulfate	104 (10.6%)	21	19.7%	13.9%-26.2%
Spinal cord stimulator (SCS)	119 (12.1%)	24	19.7%	14.2%-25.8%
Tizanidine hydrochloride	77 (7.8%)	15	18.9%	12.4%-26.3%
Hydrocodone bitartrate	72 (7.3%)	12	16.3%	10.1%-23.5%
Stretching	72 (7.3%)	11	15.1%	9.0%-22.1%
Magnesium (glycinate and others)	67 (6.8%)	10	14.7%	8.6%-21.9%
Paracetamol + oxycodone hydrochloride	64 (6.5%)	9	14.0%	7.9%-21.2%
Pregabalin	260 (26.5%)	36	13.8%	10.5%-17.4%
Tramadol hydrochloride	109 (11.1%)	14	12.9%	8.2%-18.3%
Cannabidiol (CBD)	79 (8.04%)	10	12.7%	7.4%-19.0%
Muscle relaxants	65 (6.5%)	8	12.4%	6.7%-19.2%
Hydrotherapy	76 (7.7%)	9	12.0%	6.7%-18.2%
Massage	94 (9.6%)	11	11.8%	7.0%-17.4%
Chiropractic	65 (6.6%)	7	11.0%	5.7%-17.6%
Paracetamol + hydrocodone bitartrate	68 (6.9%)	7	10.6%	5.4%-16.9%
Duloxetine hydrochloride	135 (13.7%)	14	10.5%	6.6%-15.0%
Baclofen (baclofen intrathecal pump)	92 (9.4%)	9	10.0%	5.6%-15.4%
Gabapentin	372 (37.9%)	37	10.0%	7.6%-12.7%
Turmeric capsules / pills	74 (7.5%)	7	9.8%	5.0%-15.7%
Paracetamol (acetaminophen)	76 (7.7%)	6	8.4%	4.0%-13.8%
Physiotherapy	296 (30.1%)	21	7.2%	5.0%-9.8%
Amitriptyline hydrochloride	81 (8.2%)	5	6.8%	3.0%-11.6%
Ibuprofen	88 (9.0%)	4	5.2%	2.1%-9.4%
Transcutaneous electrical nerve stimulation	85 (8.7%)	3	4.3%	1.5%-8.2%
Acupuncture	90 (9.2%)	2	3.1%	0.9%-6.4%

472 **n, number; STW, StuffThatWorks; CI, confidence intervals; incl., including.**
473 **[a] Tried treatments were 90% normalized by the STW normalization tool (see Methods).**
474 **[b] Self-rated effectiveness = "significant improvement of condition".**
475 **[c] STW estimated ratio = binomial proportion with 90% confidence intervals (see Methods).**

476

477 The 30 treatments rated as most detrimental by participants are shown in Table 7.
478 The most detrimental (≥ 20% estimated ratios) are: epidural steroid injections (38.5%),
479 spinal injections (unspecified) (31.1%), myelogram (28.5%), epidural injections
480 (unspecified) (28.2%), surgery (21.7%), and traction (20.4%).

481 **Table 7. Most detrimental treatments, ranked by self-rated detriment (n = 982)**

Treatment tried	Total [a] n (%)	Self-rated detriment [b]		
		n	STW estimated ratio [c]	90% CI
Epidural steroid injections	37 (3.8%)	20	38.5%	28.0%-49.5%
Spinal injections (unspecified)	21 (2.1%)	11	31.1%	19.6%-43.8%
Myelogram	7 (0.7%)	6	28.5%	14.9%-44.2%
Epidural injections (unspecified)	64 (6.5%)	22	28.2%	20.4%-36.6%
Surgery (unspecified)	24 (2.4%)	8	21.7%	12.1%-32.8%
Traction	7 (0.7%)	4	20.4%	8.8%-34.8%
Recurrent surgeries	10 (1.0%)	4	18.1%	7.7%-31.2%
Caudal epidural injection	6 (0.6%)	3	17.0%	6.3%-30.9%
Hydrocortisone, incl. cortisone injections	21 (2.1%)	5	15.6%	7.2%-26.0%
Spinal cord stimulator (SCS) implant	28 (2.9%)	6	15.4%	7.6%-24.9%
Nerve blocks (unspecified)	22 (2.2%)	5	15.2%	7.0%-25.4%
Facet joint injection	19 (1.9%)	4	13.7%	5.7%-23.9%
Fentanyl (patch and other routes)	91 (9.3%)	12	12.0%	7.3%-17.4%
Spinal cord stimulator (SCS)	119 (12.1%)	15	11.7%	7.5%-16.5%
Physiotherapy	297 (30.2%)	35	11.4%	8.6%-14.5%
Gabapentin	372 (37.9%)	37	9.8%	7.4%-12.3%
Chiropractic	66 (6.7%)	7	9.6%	4.9%-15.3%
Pregabalin	292 (26.7%)	25	9.3%	6.6%-12.3%
Methadone	36(3.7%)	4	9.3%	3.8%-16.6%
Opioids (unspecified)	63 (6.4%)	6	8.7%	4.2%-14.3%
Corticosteroids (unspecified), incl. steroid injections (unspecified)	54 (5.5%)	5	8.4%	3.8%-14.3%
Amitriptyline	82 (8.3%)	7	8.0%	4.1%-12.9%
Morphine sulfate	104 (10.6%)	8	7.4%	3.9%-11.7%
Muscle relaxants	66 (6.7%)	5	7.2%	3.2%-12.3%
Duloxetine hydrochloride	136 (13.8%)	9	6.5%	3.6%-10.1%
Ketamine hydrochloride (ketamine infusions)	65 (6.6%)	4	6.1%	2.4%-10.9%
Naltrexone hydrochloride (low-dose naltrexone)	68 (6.9%)	4	5.8%	2.4%-10.5%
Acupuncture	91 (9.3%)	4	4.6%	1.8%-8.3%
Pain relief medications (unspecified)	97 (9.9%)	4	4.4%	1.8%-7.9%
Oxycodone hydrochloride	230 (23.4%)	3	2.0%	0.8%-3.7%

482 **n, number; STW, StuffThatWorks; CI, confidence intervals; incl., including.**
483 **[a] Tried treatments were 90% normalized by the STW normalization tool (see Methods).**
484 **[b] Self-rated detriment = "significant worsening of condition".**
485 **[c] STW estimated ratio = binomial proportion with 90% confidence intervals (see Methods).**

486

487 Comparing Tables 6 and 7, it is evident that for several of the interventions that
488 appear on both lists, reports of an effective versus detrimental effect registered similar
489 numbers. For example, 37 respondents reported that gabapentin was effective, while an
490 equal number reported that it was detrimental.

Discussion

This preliminary investigation, functioning as a foundation for subsequent analytical frameworks, represents the most comprehensive patient-reported cross-sectional study of arachnoiditis documented to date. In addition to demonstrating significant recruitment potential through leveraging support groups and social media to study a rare condition, our research not only consolidates what is already known about arachnoiditis but also presents several new findings.

Prevalence according to demographics

Female participants comprised 75.9% of respondents in our study. This compares with 45.5% in a 2024 systematic review of 147 studies (510 cases) [7], suggesting a more balanced sex distribution in the broader literature. Other large (n ≥ 80) case series not covered in the systematic review have shown variable sex distributions, with female proportions ranging from 33% to 81% [4,12,28,34].

The true incidence of arachnoiditis and its sex ratio have not been well defined and may depend on causal factors, highlighting a need for further epidemiological studies. It is possible that the female predominance seen in our study represents greater prevalence in females. Autoimmunity may play a role in the pathophysiology of arachnoiditis, and the majority of autoimmune conditions are more common in females [90,91]. Another risk factor specific to females is obstetric epidural anesthesia. When carried out properly, epidural anesthesia is an extremely rare cause of arachnoiditis [30,92,93] however as up to two-thirds of females in developed countries undergo this procedure during childbirth [94], the sheer volume of cases augments the prevalence of this complication in proportion to the

514 substantial number of procedures performed. It is also possible that one of the contributors
515 to sex ratio imbalance in our study could be related to recruitment through social networks,
516 in which females tend to be more engaged [95,96].
517
518 In terms of age distribution, 73.1% of our respondents were ≥ 46 years old, which is
519 older than the mean age of 44.2 years (standard deviation [SD] 17.53) reported in the 2024
520 systematic review [7]. This difference likely reflects our cross-sectional design, which
521 captures individuals with established arachnoiditis rather than those at initial diagnosis.
522 However, our participants' ages fall within the SD of the review findings [7], and align with
523 the aforementioned case series, which report median or mean ages of 48.4 to 61.3 years
524 [4,12,28,34]. Importantly, our work adds insight as to the age of initial symptom onset,
525 which is spread across earlier age groups, with 53.6% ≤ 45 years.

526 Symptoms of arachnoiditis

527 The arachnoiditis symptoms we report are consistent with previous studies
528 [1,4,10,12,34], however, our work further elaborates symptom descriptions, and also
529 identifies which symptoms are most indicative of the condition. Pain and sensory
530 disturbances were predominant among the most frequently reported symptoms (35/71
531 symptoms), and include burning sensations, electric shock sensations, shooting pain,
532 numbness, tingling, and formication (sensations of insects crawling on the skin). All these
533 symptoms had high STW cross-conditions scores suggesting greater specificity for
534 arachnoiditis. Formication has been described in previous reports [12,34], although it is not
535 unique to arachnoiditis, having been reported with other neurological conditions [97].
536 Aldrete [12] has proposed neurophysiological explanations for many of the sensory
537 symptoms in arachnoiditis, including formication, and also described pain distribution

538 patterns that may not always follow nerve dermatomes but may be more regional or patchy
539 in nature, reminiscent of findings in tethered cord syndrome [98,99].
540
541 Beyond sensory symptoms, signs of motor nerve damage or irritation are also
542 frequently reported in our study, including weakness, foot drop, muscle spasms, cramps
543 and twitching. Muscle related symptoms such as spasms, cramps and fasciculations have
544 been previously reported [1,12] however they lack detailed characterization in the literature,
545 warranting more comprehensive study to better understand their pathophysiology, temporal
546 progression and their relationship to the location of spinal cord involvement. Motor
547 symptoms suggest that electrodiagnostic tests may be useful, however, it has been noted
548 that such tests do not produce a consistent pattern that can be identified as arachnoiditis
549 for diagnostic purposes [3,4,12]. Yet, the potential utility of these tests has not been
550 systematically investigated in individuals with arachnoiditis, particularly among those with a
551 spectrum of motor nerve dysfunction, as has been studied in related conditions, such as
552 adult tethered cord [100], syringomyelia [101], and Tarlov cysts [102,103]. Such research
553 could prove beneficial for diagnosis, especially in suspected cases, as well as for
554 monitoring disease progression.
555
556 An array of other physical signs and symptoms were described in people living with
557 arachnoiditis in our cohort. Symptoms localized to the feet were common, with 17.2%
558 reporting numbness, 16.6% pain, and 14.4% burning sensation, all of which were
559 associated with high STW cross-condition scores > 6. Exclusion of more common causes
560 of sensory dysesthesias in the feet seen in other conditions, along with the presence of

561 other characteristic findings and risk factors consistent with arachnoiditis, may lead to more
562 accurate diagnosis and shorten time to diagnosis.
563
564 Eight diverse types of head and neck symptoms were reported by study participants,
565 led by headache (22.3%), however none produced a STW cross-condition score indicating
566 a high specificity for arachnoiditis. Bladder and bowel symptoms, led by “unspecified
567 bladder issues” (11.9%) and incontinence (10.3%), have also been reported in many
568 previous studies [1,12,34,47] with only “unspecified bladder symptoms” producing a cross-
569 condition score > 6.

570 Earliest presenting symptoms

571 We sought to characterize the earliest presenting symptoms of arachnoiditis given
572 there is some evidence that disease progression might be arrested or reversed in some
573 individuals with early intervention. Early recognition may also provide patients with timely
574 explanations for their symptoms and help to reduce diagnostic uncertainty. Our preliminary
575 results suggest that the character and pattern of earliest symptoms do not differ significantly
576 from general reported symptoms. Pain and altered sensation predominated among the top
577 20 earliest symptoms. Future studies will benefit from gathering information about initial
578 symptoms as soon as possible after diagnosis to gain a more accurate picture of symptom
579 development.

580 Nature of aggravating factors

581 The most frequently reported aggravating factors, “sitting or sitting too long” and
582 “standing or standing too long”, were reported by 62.5% and 58.3% of the study population,
583 respectively. The positional nature of these and other commonly reported aggravating

factors is noteworthy, both in our study and in previous reports. Porcelli and Tennant [34] reported that 87.5% of their 80 subjects with lumbosacral arachnoiditis experienced relief of symptoms upon standing up, 86.3% reported that standing up for too long caused the need to lie down, and 83.8% of their subjects found that it hurt to lie flat on their back. Similar positional symptoms have been documented in case reports of arachnoiditis [18,104,105]. The specific positions that aggravate symptoms may be correlated with the spinal levels that are affected by arachnoiditis (not assessed in this study), such that the inflamed or adhered nerves are compressed or stretched in certain positions. In tethered cord syndrome, positional symptoms caused by elongation of the lumbar spine have been reported [98], and a potentially analogous mechanism may be relevant in some cases of arachnoiditis. Positional aggravating factors may also be reflective of their effect in increasing CSF pressure in various parts of the spine against an arachnoiditis-induced CSF flow disturbance, or they may be suggestive of a particular complication. In future studies, we intend to correlate the level of spinal involvement with specific aggravating factors.

Movements that provoked symptoms were categorized as walking, lifting, transitional movements, and activities that bend, twist or stretch. Symptom exacerbation likely involves multifactorial mechanisms. For example, when a nerve is inflamed or irritated, it becomes more sensitive to mechanical forces like stretching or compression [106]. Additionally, in disease conditions causing mechanical nerve compromise such as tethered cord syndrome or radiculopathy, stretching of nerve roots contributes to pathophysiology due to limitation in nerve root movement or temporary ischemic changes [50,107,108], a finding which has been extended to arachnoiditis [50].

Activities related to lifting may involve additional mechanisms. During lifting the core abdominal muscles are activated, and in heavy lifting a Valsalva maneuver may also occur. These muscle activations increase intra-abdominal and intra-thoracic pressure transiently [109], both of which increase CSF pressure or volume [110–113]. Such changes can alter CSF flow in individuals with arachnoiditis or increase pressure against the nerve roots, potentially exacerbating neurologic symptoms. Increases in CSF pressure have been associated with symptom exacerbation in individuals with related spinal conditions including syringomyelia [114] and Tarlov cysts [103]. Patients with syringomyelia are generally advised to avoid deadlifts, as the Valsalva maneuver can result in deleterious syrinx expansion [114].

Spinal comorbidities, which were common among study participants, present additional complexities when interpreting aggravating factors, as they may share some positional and movement-related triggers.

Physical exertion intensity commonly caused exacerbation of symptoms. While research shows benefits of physical activity for chronic or neuropathic pain [115–118], low or low-moderate intensity exercise is typically recommended—aligning with our findings. Individually tailored recommendations for physical activity and activity modification in individuals with arachnoiditis are generally advised.

Some aggravating factors described in our study, while commonly reported, showed low STW cross-condition scores and can be seen across multiple conditions beyond

631 arachnoiditis. These include variations in the weather or temperature, poor sleep, stress,
632 anxiety, and lack of movement.

633 Our analysis has the potential to facilitate the development of broader and more
634 precise clinical diagnostic criteria for arachnoiditis based on symptoms and aggravating
635 factors, improving diagnostic accuracy and differential diagnosis. This would be especially
636 important for those in whom arachnoiditis is suspected, but there are no correlative signs
637 evident in radiological studies. Furthermore, reducing or avoiding exposure to an
638 individual's known aggravating factors has practical relevance for symptom management.
639 Since neuropathic pain in individuals with arachnoiditis is often delayed in onset and
640 protracted in duration relative to the inciting activity [1] the empiric pacing of known
641 aggravating activities requires anticipation to avoid triggering symptom flares.

642 Comorbid conditions

643 Coexisting degenerative spine conditions or anatomic abnormalities are frequently
644 listed as comorbidities in our study, including spinal stenosis, cauda equina syndrome,
645 scoliosis, and disc-related pathologies such as degenerative disc disease and disc
646 herniation. All of these conditions, except scoliosis, had high STW cross-condition scores,
647 suggesting they correlate strongly with arachnoiditis. While these conditions have been
648 associated with lumbar arachnoiditis in many earlier reports [4,7,12,14,28], they also lead to
649 invasive spinal interventions—a well described risk factor that is often concomitantly
650 reported in arachnoiditis studies (not ascertained in this study). However, both disc
651 pathology [29,104] and degenerative spinal conditions [28,39,49,119,120] have also been
652 identified as the sole apparent risk factor in cases of arachnoiditis with no history of spinal
653 interventions.

654

655 In a related finding, Parenti et al. [43] demonstrated that spinal comorbidities in
656 lumbar arachnoiditis have a significant relationship to arachnoiditis symptom dynamics,
657 suggesting that integrated treatment of these comorbidities may help mitigate symptom
658 progression. However, treatment decisions must carefully consider the potential for invasive
659 interventions to worsen arachnoiditis. Although Palackdharry et al. [1] reported finding no
660 evidence that surgical procedures (or lumbar puncture) in unaffected adjacent spinal levels
661 worsen existing arachnoiditis, this was reported without detail. Further studies are required.
662
663 Failed back surgery syndrome was listed by 10% of our study participants as a
664 comorbidity, consistent with previous studies [1,12,14,121]. Failed back surgery syndrome
665 is an umbrella term for a variety of pathological conditions, including arachnoiditis, that can
666 result in persistent symptoms after spine surgery. The extent to which symptomatic
667 lumbosacral arachnoiditis may be present prior to spinal surgery is unknown. This may be
668 difficult to ascertain due to the overlap of symptoms between arachnoiditis and the
669 underlying pathology necessitating surgery. In their study of patients undergoing surgery for
670 spinal stenosis—a condition that is both a known cause of arachnoiditis due to mechanical
671 irritation and creates confounding radiological findings due to the narrowed spinal canal
672 [119,120,122]—Kawauchi et al. [71] performed pre-operative myeloscopic assessment of
673 the subarachnoid space. They found that all patients demonstrated some degree of pre-
674 operative arachnoid adhesions, however those with marked adhesions experienced worse
675 outcomes after the spinal stenosis surgery. Where surgeons are interested in determining if
676 arachnoiditis is present pre-operatively and radiological findings are ambiguous, the
677 expanded symptoms list may assist—particularly when patients report additional symptoms

678 more suggestive of arachnoiditis (for example, burning sensations in the feet, or
679 formication) than those typically associated with their degenerative condition.
680
681 Our study revealed a 9.8% prevalence of Tarlov cysts, approximately twice the
682 estimated prevalence in the general population [123], supporting the association with
683 arachnoiditis suggested in previous reports [34,37,38]. A further 8.0% of respondents
684 reported a diagnosis of EDS, which is higher than the estimated prevalence of joint
685 hypermobility spectrum disorders in the general population (3-4%), and considerably higher
686 than typical rates of EDS [124], consistent with this association in earlier reports [34,35].
687 This association, however, was not explicitly noted in a 2017 comprehensive review of the
688 neurological and spinal manifestations of EDS [125], suggesting it may be
689 underrecognized. Fibromyalgia was reported as a comorbidity in 25.0% of study
690 participants but produced a low STW cross-condition score. Given that fibromyalgia is a
691 diagnosis of exclusion, with some symptoms overlapping those attributed to arachnoiditis,
692 fibromyalgia could be misdiagnosed in patients with arachnoiditis. However, fibromyalgia
693 demonstrates similarly high comorbid rates across various chronic conditions, including
694 inflammatory arthritis, autoimmune disorders, centralized pain syndromes and neurological
695 diseases, where it typically adversely affects quality of life and health status in these
696 individuals [126]. The substantial prevalence of fibromyalgia in our cohort suggests it may
697 represent a genuine and clinically important comorbidity in arachnoiditis patients.
698
699 Depression and anxiety, commonly associated with chronic pain conditions, were
700 also frequently reported as comorbidities in our study. Even though osteoarthritis, reported
701 by 12.4% of respondents, is highly prevalent in the general population and less indicative of

arachnoiditis according to a low cross-condition score, it should be noted that people with arachnoiditis and syrinx may experience Charcot-type neuropathic arthropathy in a variety of joints [127]. Hypertension, another comorbidity with a low cross-condition score, is also prevalent in the general population. However, episodic or paroxysmal surges of severe hypertension may be a sign of autonomic dysreflexia in individuals with arachnoiditis or syrinx [65,128,129]. In future studies, gathering more detailed information regarding comorbidities will elucidate etiological factors and predisposing conditions.

Tried treatments

Participants in our study attempted a wide range of treatments, including pharmaceutical analgesics, muscle relaxants, interventional pain procedures, over-the-counter pain relievers, natural supplements, and physical therapies. This range highlights that current approaches are predominantly focused on symptom management rather than addressing underlying inflammatory or disease-modifying mechanisms.

Confirming the consensus from earlier literature reports [1,3,11,12], our study demonstrates that arachnoiditis remains challenging to treat. Treatment effectiveness rates ranged from 3.1% to 28.1%, with most treatments showing less than 15% effectiveness, demonstrating the critical need for developing more effective treatment strategies for this condition. Importantly, the wide confidence intervals for effectiveness indicate considerable uncertainty in these estimates, meaning the true rates could be much lower or higher.

Among the treatments, it is notable that the most frequently tried treatments are not the same as those rated as most effective. The most commonly tried treatments—gabapentin (37.9% of participants), physiotherapy (30.1%), and pregabalin (26.5%)—

726 showed relatively modest effectiveness rates of 10.0%, 7.2%, and 13.8% respectively. This
727 pattern likely reflects standard clinical practice, where these treatments are commonly
728 prescribed as first-line therapies for neuropathic pain due to their established use and
729 familiarity among clinicians. In contrast, several less frequently used treatments
730 demonstrated higher effectiveness rates.
731
732 Lose dose naltrexone emerged as the most effective treatment (28.1%
733 effectiveness) while being tried by only 6.8% of participants. Several recent reports propose
734 naltrexone as a treatment option for arachnoiditis [1,11,34], however there has been an
735 absence of studies evaluating it in arachnoiditis patients. The preliminary data from our
736 study suggests that naltrexone offers beneficial effects, with few detrimental reports,
737 making it an attractive candidate for further study.
738
739 Ketamine also showed high effectiveness rates (24.8%) while being tried by only
740 6.6% of participants. Its limited use likely reflects significant practical constraints, including
741 controlled substance regulations, requirements for specialized infusion facilities, and
742 notable side-effects. Many of the highest-rated treatments face similar implementation
743 challenges. These constraints highlight the broader challenge in chronic pain management
744 of balancing therapeutic efficacy with safety and regulatory concerns.
745
746 Spinal cord stimulators (SCS) showed a moderate patient-reported effectiveness
747 rate of 19.7%, placing them among the more effective treatments within our study.
748 However, a considerable proportion (11.7%) of individuals who reported using this modality
749 also rated SCS as detrimental. SCS have been recommended as treatment modality option

750 for arachnoiditis [1], although it has been noted that higher effectiveness rates are typically
751 observed among specially selected patient subgroups. Further investigation into the
752 specific factors contributing to treatment detriment in individuals with arachnoiditis,
753 including patient selection criteria and optimal timing of intervention, will be important for
754 future research.
755
756 While non-pharmacologic therapies such as stretching, hydrotherapy, and massage
757 showed only modest effectiveness rates in our study (15.1%, 12.0%, and 11.8%
758 respectively), their favorable safety profiles make them important considerations for patient
759 care, particularly as components of multimodal treatment approaches. Importantly, our
760 findings from the assessment of aggravating factors indicate that certain physical activities,
761 including stretching and overexertion, can worsen symptoms in some patients. Therefore,
762 careful monitoring and gradual, individualized implementation of these therapies is
763 essential.
764
765 Beyond the commonly reported treatments in our results, many other medications
766 and interventions that have been identified as potentially beneficial in recent arachnoiditis
767 papers were not represented in sufficient numbers in our study population to appear in our
768 results. These include, but are not limited to, ketorolac [34], diclofenac and other non-
769 steroidal anti-inflammatories [3,65], corticosteroids [11,34,104,130], electrotherapeutic
770 agents [65], metformin [1], cerebrolysin [1], eicosapentaenoic acid (fish oil) [104], newer
771 formulations of curcumins [1,65], cognitive behavioral therapy to help modulate pain
772 perception [3], and neural mobilization [1,105]. Similarly, many authors recommend
773 multimodal and interprofessional pain management strategies, however there were not any

774 multi-drug regimens or combination therapies reported with sufficient frequency to appear
775 in our results.
776
777 Notably, the prevalence of corticosteroid use may be underestimated in our sample
778 as a consequence of steroid medications being listed individually (e.g., dexamethasone,
779 methylprednisolone) and therefore counted individually rather than as a collective category.
780 Further, the open-text survey questions did not differentiate between treatments for routine
781 daily symptom management versus periodic symptom flares. Since corticosteroids are
782 frequently used to treat symptom flares and reduce inflammation [11,34,65,130],
783 participants may have considered only their routine treatments when responding.
784
785 Interestingly, analysis of data comparing treatments rated as effective versus
786 detrimental revealed a paradoxical pattern wherein certain interventions received
787 contradictory evaluations from different respondents. This may reflect inter-individual
788 physiological differences, variations in disease severity or stage at the time of treatment,
789 therapeutic efficacy that diminishes over time, or differences in underlying etiology. Different
790 causes may involve distinct inflammatory patterns or therapeutic windows. In the current
791 study, however, we were unable to compare the efficacy of treatments over time or across
792 different etiologies.
793
794 The most detrimental treatments in our study primarily consisted of invasive spinal
795 interventions, reflecting their shared capacity to induce spinal cord irritation and
796 inflammation directly though physical or mechanical trauma to already compromised neural

797 tissues. This finding aligns with existing literature [1] that identifies invasive spinal
798 procedures as risk factors for arachnoiditis development.

799 Contribution of artificial intelligence (AI)/machine learning

800 Natural language processing techniques, coupled with artificial intelligence and
801 machine learning algorithms, facilitate the analysis of extensive datasets, and have the
802 potential to generate valuable and unique insights. The findings from our study offer
803 considerable new details about arachnoiditis and would not have been feasible without an
804 international online platform and the novel AI tools employed. The STW cross-condition
805 score is particularly unique in its ability to compare individual symptoms, comorbidities and
806 aggravating factors across very large numbers of people with and without arachnoiditis on
807 the online platform, with each receiving a score indicating its specificity for the condition.
808
809 AI-generated data output, however, requires careful review and interpretation. For
810 example, in the present study, some similar or identical symptoms were tabulated by AI
811 machine learning as separate entities, such as “tingling” and “pins and needles”. This may
812 have resulted from an incomplete ability of natural language processing to detect various
813 open-label text terms as being synonymous. Further training of AI may be required to better
814 recognize and properly categorize and group terms. Use of AI and machine learning to
815 process and categorize large datasets and images in future studies may help to further
816 establish accurate diagnostic criteria for arachnoiditis, including improved MRI
817 interpretation [131,132].

Study limitations

The most notable study limitations include reliance on self-reported data with a potential for recall bias. Furthermore, while the use of open-text survey questions enables a wide range of responses to facilitate learning as much as possible about the condition in an unbiased manner, this approach may be associated with more unintentional omissions compared to selecting options from a checklist.

This study did not address the duration, frequency and severity of symptoms, including symptom flares, and therefore cannot therefore provide an overview of how pain and other symptoms differ between participants. In addition, the aggregate nature of the data provided, combined with the absence of data on disease location, extent, or suspected causes, prevented analysis by these variables, which may have yielded valuable insights.

As a cross-sectional study, our data on treatment effectiveness does not offer the same level of evidence as controlled clinical trials, and our binary effectiveness measure (self-reported significant improvement of condition) may underestimate treatments that provide modest but clinically relevant symptom relief. However, our aggregated findings may reveal meaningful trends and identify treatments suitable for future studies or individual trials. Assessment of treatment effectiveness is also complicated by the poorly defined natural history of arachnoiditis, where some individuals experience disease progression, and others remain static [2,4]. Treatments that successfully prevent deterioration rather than provide improvement may represent meaningful clinical success in some patients but may not be assessed as such. In addition, given that our results revealed a wide variety of treatments being used, another limitation is that our data for effectiveness

842 is limited to the 30 most frequently reported treatments – therefore less frequently used, but
843 potentially more effective treatments may not have been captured. Specific adverse events
844 or detrimental responses that might have led to discontinuation of a given treatment were
845 beyond the scope of this present study, as were questions that could link specific
846 treatments or sequencing of treatments to the early or advanced stage of disease for an
847 individual.
848
849 Generalizability of our study may be limited given recruitment methods relying on
850 social networks, which favors females and those with higher socioeconomic backgrounds
851 [133]. In a similar vein, our respondents are predominantly of European ethnicity, which
852 may be related to the survey being available only in the English language, or also the lower
853 rates of social media involvement among other ethnic groups [134]. Similarly, completion of
854 online questionnaires requires digital literacy and stamina, which could prevent those with
855 significant disability levels from responding. Despite the potential for selection bias and lack
856 of full representation of the entire population of those living with arachnoiditis, our findings
857 remain consistent with earlier reports.

858 Future directions

859 Significant areas of unmet need include consensus development of diagnostic
860 criteria to reduce delays in diagnosis, establishment of natural history studies to better
861 delineate differences between individuals in initiation and progression of disease, and
862 discovery and development of more effective treatments.
863
864 Greater awareness of arachnoiditis and its causes, along with the development of
865 more explicit diagnostic criteria, potentially including the findings in this study, will aid in

accelerating diagnosis and reducing the diagnostic “odyssey” so common in rare diseases [135,136]. Such enhanced recognition by the broader medical community, and improved understanding of the complications, can bring about a three-fold benefit. First, to highlight the essential need for multi-disciplinary care; second, to stimulate pharmaceutical industry and stakeholder interest in initiating and funding therapeutic research; and third, importantly, to benefit those individuals living with arachnoiditis who are actively seeking care, to be heard and understood by health care providers. With more information and training, providers may be less likely to be dismissive of persons affected by the condition, whose disabling symptoms frequently remain externally invisible to others, or to misattribute these symptoms to mental health issues or drug-seeking behavior [1,12,137–139].

The development of novel, more effective treatments for arachnoiditis must be a high priority as the science and understanding of modulating neuropathic and centrally mediated pain advance [73]. Given the inflammatory origin of arachnoiditis, future studies might explore whether medications that target inflammation and effectively cross the blood-brain barrier might both relieve symptoms and modify disease progression [1,16,73,140]. Treatments that prevent, stop or reverse fibrotic transformation and the consequences should be a high priority [1]. Advancements in minimally invasive spinal surgery are promising and may offer new treatment avenues for arachnoiditis patients in the future, with reduced morbidity [1]. The development of validated quality-of-life measures specifically designed for assessing interventions, like those recently developed for Tarlov cyst surgery [141], would significantly enhance our ability to measure treatment outcomes.

889 Research should focus not only on developing more effective therapies, but also on
890 identifying biomarkers or clinical predictors that can guide personalized treatment selection,
891 particularly given the potential timing-dependent efficacy of some treatments, and the
892 substantial inter-individual variation in treatment responses observed in our study. In one
893 example of such translational research, Zhang et al. [16] recently delineated differential
894 gene expression from multiple cell types in human arachnoid tissues obtained from patients
895 with and without arachnoiditis undergoing neurosurgery for Chiari malformation or
896 syringomyelia. They employed transcriptome profiling using sn-RNA seq analysis, providing
897 an avenue of discovery for new insights into the pathophysiology and signaling pathways
898 characterizing adhesive arachnoiditis, with the possibility of biomarker discovery.
899
900 To support such research endeavors, an arachnoiditis international patient registry
901 would enable comprehensive data collection across diverse populations over time and
902 facilitate cross-disciplinary research collaboration. Such a registry could inform future
903 prospective study design by employing a relational database in which sequential treatments
904 are linked with clinical disease stage and treatment outcomes. Quantification of treatment
905 effects can be accomplished through incorporation of validated patient reported outcome
906 instruments evaluating quality of life, pain, disability, and health-related economic costs. It
907 would be advantageous to store select anonymized patient health data such as MRI, EMG
908 and other reports to confirm diagnosis, clarify clinical findings and elaborate upon patient
909 generated data. Serial collection of longitudinal data on symptoms and level of disability
910 would help to better define the natural history of progression in our sample. This would also
911 permit interrogation of the larger dataset to explore any correlations that may exist between
912 the presumptive inciting causes of an individual's arachnoiditis, the disease distribution

913 within the spinal cord, and the stage and severity of the condition. Such an approach might
914 also enable exploration of whether certain subsets of patients respond differentially to
915 various treatments or experience different rates of disease progression.

916 Conclusion

917 This report describes the largest reported observational study on arachnoiditis to
918 date. Our findings support and consolidate what is already known about the condition while
919 advancing several new and important observations regarding age of first symptom onset,
920 range of symptoms, aggravating factors, comorbid conditions and self-assessment of tried
921 treatments, potentially facilitating more accurate diagnostic criteria and guiding future
922 research questions. This early attempt at employing AI/machine learning, combined with
923 recruitment potential via disease advocacy groups, exceeds traditional attempts at
924 recruiting a cohort of sufficient size to improve our understanding of a rare disease.

925 Acknowledgements

926 The study was approved by the Sheba Medical Center Institutional Review Board
927 (IRB authorization #7356-20-SMC) in Israel and conducted according to the principles of
928 the Declaration of Helsinki.
929
930 The authors wish to thank all the individuals living with arachnoiditis who participated
931 in the survey. We acknowledge StuffThatWorks Ltd (www.stuffthatworks.health/introduction)
932 for use of their platform, data aggregation and insights generation. We are grateful to Eve
933 Blackburn for her substantial participant recruitment efforts. We thank Michele Hansen PhD
934 MPH and Richard Dobson MD for reviewing the manuscript, and Rob Lloyd PhD for his

review of the CSF dynamics content. We are grateful to Enoch Carter for assistance with data preparation. We appreciate the continuing graphic design support of Matthew Churchward and Eve Blackburn. We dedicate this paper to the memory of ACMCRN co-founder and former VP of Research, Terri Lewis, PhD, who provided vital input into the concept and design of this study.

References

[1] Palackdkharry CS, Wottrich S, Dienes E, Bydon M, Steinmetz MP, Traynelis VC. The leptomeninges as a critical organ for normal CNS development and function: first patient and public involved systematic review of arachnoiditis (chronic meningitis). PLOS One 2022;19. doi: 10.1371/journal.pone.0274634. PMID: 36178925.

[2] Mastorakos P, Jonathan Pomeraniec I, Bryant JP, Chittiboina P, Heiss JD. Flexible thecoscopy for extensive spinal arachnoiditis. J Neurosurgery Spine 2022;36:325–35. doi:10.3171/2021.4.SPINE21483. PMID: 34598155.

[3] Peng H, Conermann T. Arachnoiditis. StatPearls[Internet]. Treasure Island (FL): StatPearls Publishing; 2024.

[4] Long DM. Chronic adhesive spinal arachnoiditis: pathogenesis, prognosis, and treatment. Neurosurg Q 1992;2:296–320.

[5] Holmström U, Tsitsopoulos PP, Flygt H, Holtz A, Marklund N. Neurosurgical untethering with or without syrinx drainage results in high patient satisfaction and favorable clinical outcome in post-traumatic myelopathy patients. Spinal Cord 2018;56:873–882. doi: 10.1038/s41393-018-0094-y. PMID: 29588484.

[6] Inoue Y, Nemoto Y, Ohata K, Daikokuya H, Hakuba A, Tashiro T, et al. Syringomyelia associated with adhesive spinal arachnoiditis: MRI. Neuroradiology 2001;43:325–30. doi: 10.1007/pl00006049. PMID: 11338419.

[7] Zhang W, Liu Z, Wang K, Zhang L, Liu S, Zhang X, et al. Spinal adhesive arachnoidopathy, the disorder more than simply adhesive arachnoiditis: a comprehensive systematic review of 510 cases. CNS Neurosci Ther 2024;30:e70084. doi: 10.1111/CNS.70084. PMID: 39435986.

[8] Wang R, Zhou R, Chen Z, Gao S, Zhou F. The glial cells respond to spinal cord injury. Front Neurol 2022;13. doi: 10.3389/fneur.2022.844497. PMID: 35599739.

[9] Holmström U, Tsitsopoulos PP, Holtz A, Salci K, Shaw G, Mondello S, et al. Cerebrospinal fluid levels of GFAP and pNF-H are elevated in patients with chronic spinal cord injury and neurological deterioration. Acta Neurochir (Wien) 2020;162:2075–86. doi: 10.1007/S00701-020-04422-6. PMID: 32588294.

[10] Anderson TL, Morris JM, Wald JT, Kotsenas AL. Imaging appearance of advanced chronic adhesive arachnoiditis: a retrospective review. AJR Am J Roentgenol 2017;209:648–55. doi: 10.2214/AJR.16.16704. PMID: 28639826.

[11] Maillard J, Batista S, Medeiros F, Farid G, Santa Maria PE, Perret CM, et al. Spinal adhesive arachnoiditis: a literature review. Cureus 2023;15:e33697. doi: 10.7759/cureus.33697. PMID: 36788823.

[12] Aldrete J. Suspecting and diagnosing arachnoiditis. Pract Pain Manag 2006;6.

[13] Guyer DW, Wiltse LL, Eskay ML, Guyer BH. The long-range prognosis of arachnoiditis. Spine (Phila Pa 1976) 1989;14:1332–41. doi : 10.1097/00007632-198912000-00010. PMID: 2617363.

[14] Burton C V. Lumbosacral arachnoiditis. Spine (Phila Pa 1976) 1978;3:24–30. doi: 10.1097/00007632-197803000-00006. PMID: 148106.

[15] Orphanet. Arachnoiditis 2024. https://www.orpha.net/en/disease/detail/137817.

[16] Zhang W, Zhang X, Wang K, Liu Z, Zhang L, Liu S, et al. Single-nucleus transcriptome profiling provides insights into the pathophysiology of adhesive arachnoiditis. Biochim Biophys Acta Mol Basis Dis 2025;1871. doi: 10.1016/j.bbadis.2024.167655. PMID: 39755217.

[17] Brodbelt AR, Stoodley MA. Post-traumatic syringomyelia: A review. Journal of Clinical Neuroscience 2003;10:401–8. doi: 10.1016/S0967-5868(02)00326-0. PMID: 12852875.

[18] Jain N, Jaunozolina L, Putraima I, Auslands K, Millers A. Delayed spinal arachnoiditis with syringomyelia following aneurysmal subarachnoid haemorrhage: a case report with patient experience. Spinal Cord Ser Cases 2024;10. doi:/ 10.1038/S41394-024-00654-1. PMID: 38858362.

[19] Laitt R, Jackson A, Isherwood I. Patterns of chronic adhesive arachnoiditis following Myodil myelography: the significance of spinal canal stenosis and previous surgery. Br J Radiol 1996;69:693–8. doi:10.1259/0007-1285-69-824-693. PMID: 8949669.

[20] Nadeem SF, Baig AN, Tariq QUA, Shamim MS. Spinal arachnoiditis and syringomyelia: review of literature with emphasis on postinfectious inflammation and treatment. Surg Neurol Int 2022;13. doi: 10.25259/SNI_383_2022. PMID: 35928312.

[21] Nannini S, Koshenkova L, Baloglu S, Chaussemy D, Noël G, Schott R. Immune-related aseptic meningitis and strategies to manage immune checkpoint inhibitor therapy: a systematic review. J Neurooncol 2022;157:533–50. doi: 10.1007/s11060-022-03997-7. PMID: 35416575.

[22] Di Ieva A, Barolat G, Tschabitscher M, Rognone E, Aimar E, Gaetani P, et al. Lumbar arachnoiditis and thecaloscopy: brief review and proposed treatment algorithm. Cent Eur Neurosurg 2010;71:207–12. doi: 10.1055/s-0029-1243201. PMID: 20027540.

[23] Kainer MA, Reagan DR, Nguyen DB, Wiese AD, Wise ME, Ward J, et al. Fungal infections associated with contaminated methylprednisolone in Tennessee. New England Journal of Medicine 2012;367:2194–203. doi: 10.1056/nejmoa1212972. PMID: 23131029.

[24] Smith RM, Schaefer MK, Kainer MA, Wise M, Finks J, Duwve J, et al. Fungal infections associated with contaminated methylprednisolone injections. New England Journal of Medicine 2013;369:1598–609. doi: 10.1056/nejmoa1213978. PMID: 23252499.

[25] Centers for Disease Control and Prevention. Spinal and paraspinal infections associated with contaminated methylprednisolone acetate injections – Michigan, 2012-2013. MMWR Morb Mortal Wkly Rep. 2013 May 17;62(19):377-8.

[26] World Health Organization. WHO. 2023. Outbreak of suspected fungal meningitis associated with surgical procedures performed under spinal anaesthesia in US & Mexico 2023.

[27] Practice advisory for the prevention, diagnosis, and management of infectious complications associated with neuraxial techniques: an updated report by the American Society of Anesthesiologists Task Force on Infectious Complications Associated with Neuraxial Techniques and the American Society of Regional Anesthesia and Pain Medicine. Anesthesiology 2017;126:585–601. doi: 10.1097/ALN.0000000000001521. PMID: 28114178.

[28] El Homsi M, Gharzeddine K, Cuevas J, Arevalo-Perez J, Rebeiz K, Khoury NJ, et al. MRI findings of arachnoiditis, revisited. Is classification possible? Journal of Magnetic Resonance Imaging 2021;54:904–9. doi: 10.1002/jmri.27583. PMID: 33644967.

[29] Ottaiano AC, de Freddi TAL. “Sticky Spine”: A review of the imaging findings for spinal arachnoiditis. Neurographics 2022;12:169–75. doi: 10.3174/ng.2100062.

[30] Brenna CTA, Khan S, Poots C, Brull R. Association between perioperative neuraxial local anesthetic neurotoxicity and arachnoiditis: a narrative review of published reports. Reg Anesth Pain Med 2024;49:726–50. doi: 10.1136/RAPM-2023-104941. PMID: 38050164.

[31] De La Motte MB, Abbas R, Jouan F, Van Gysel D, Chauveheid MP, Papo T, et al. Systemic inflammatory disorders in patients admitted for aseptic meningitis. Clin Med 2018;18:132–137. doi: 10.7861/CLINMEDICINE.18-2-132. PMID: 29626017.

[32] Abhinav K, Bradley M, Aquilina K, Patel NK. Spinal arachnoiditis and cyst formation with subarachnoid haemorrhage. Br J Neurosurg 2012;26:574–5. doi: 10.3109/02688697.2011.651512. PMID: 22299598.

[33] Khan MU, Anthony J, Devlin J, Fraser A. Adhesive arachnoiditis in mixed connective tissue disease: a rare neurological manifestation. BMJ Case Rep 2016. doi: 10.1136/bcr-2016-217418. PMID: 27986694.

[34] Porcelli MJ, Tennant FS. Primer on Adhesive Arachnoiditis. JOFP-CA 2024;2. doi: 10.58858/010203.

[35] Tonk SS, Wilson GN. Similar Ehlers–Danlos Syndrome profiles produced by variants in multiple collagen genes. DNA 2025;5:11. doi: 10.3390/DNA5010011.

[36] Pasoglou V, Janin N, Tebache M, Tegos TJ, Born JD, Collignon L. Familial adhesive arachnoiditis associated with syringomyelia. American Journal of Neuroradiology 2014;35:1232–6. doi: 10.3174/ajnr.A3858. PMID: 24481329.

[37] Luchtmann M, Klammer A, Iova MA, Roth A, Mawrin C, Warnke JP. Combined endoscopic and microsurgical treatment of Tarlov cysts. Interdisciplinary Neurosurgery 2024;36:101925. doi: 10.1016/j.inat.2023.101925.

[38] Vaughan D, Bolger C, O'Brien DF. An interesting case of primary spinal arachnoiditis. Br J Neurosurg 2012;26:555–7. doi: 10.3109/02688697.2012.663516. PMID: 22369357.

[39] Arai A, Aihara H, Miyake S, Hanada Y, Kohmura E. Syringomyelia due to thoracic spinal stenosis with ossified ligamentum flavum. Neurol Med Chir 2011;51:157–9. doi: 10.2176/NMC.51.157. PMID: 21358164.

[40] Ross JS, Masaryk TJ, Modic MT, Delamater R, Bohlman H, Wilbur G, et al. MR imaging of lumbar arachnoiditis. AJR Am J Roentgenol 1987;149:1025–32. doi: 10.2214/AJR.149.5.1025. PMID: 3499773

[41] Hoffman G.S, Ellsworth C.A, Wells E.E, Franck W.A, Mackie R.W. Spinal arachnoiditis. what is the clinical spectrum? II. Arachnoiditis induced by Pantopaque/autologous blood in dogs, a possible model for human disease. Spine (Phila Pa 1976) 1983;8:541–51. PMID: 6648703

[42] Delamarter RB, Ross JS, Masaryk TJ, Modic MT, Bohlman HH. Diagnosis of lumbar arachnoiditis by magnetic resonance imaging. Spine (Phila Pa 1976) 1990;15:304–10. doi: 10.1097/00007632-199004000-00011. PMID: 2353276.

[43] Parenti V, Huda F, Richardson PK, Brown D, Aulakh M, Taheri MR. Lumbar arachnoiditis: does imaging associate with clinical features? Clin Neurol Neurosurg 2020;192. doi: 10.1016/j.clineuro.2020.105717. PMID: 32062307.

[44] Klekamp J. Treatment of syringomyelia related to nontraumatic arachnoid pathologies of the spinal canal. Neurosurgery 2013;72:376–89. doi: 10.1227/NEU.0b013e31827fcc8f. PMID: 23208064.

[45] Davidoff CL, Liu S, Wong JHY, Koustais S, Rogers JM, Stoodley MA. Treatment of syringomyelia in patients with arachnoiditis at the craniocervical junction. World Neurosurg 2017;107:565–73. doi: 10.1016/j.wneu.2017.08.064. PMID: 28842236.

[46] Moura da Silva LF, Buffon VA, Coelho Neto M, Ramina R. Non-schwannomatosis lesions of the internal acoustic meatus - a diagnostic challenge and management: a series report of nine cases. Neurosurg Rev 2015;38:641–8. doi : 10.1007/S10143-015-0638-Y. PMID: 25957055.

[47] Epstein NE, Agulnick MA. Perspective: Lumbar adhesive arachnoiditis (AA)/ chronic AA (CAA) are clinical diagnoses that do not require radiographic confirmation. Surg Neurol Int 2022;13. doi: 10.25259/SNI_943_2022. PMID: 36447842.

[48] Warnke JP, Köppert H, Bensch-Schreiter B, Dzelzitis J, Tschabitscher M. Thecaloscopy part III: First clinical application. Minimally Invasive Neurosurgery 2003;46:94–9. doi: 10.1055/S-2003-39341. PMID: 12761680.

[49] Tobita T, Okamoto M, Tomita M, Yamakura T, Fujihara H, Baba H, et al. Diagnosis of spinal disease with ultrafine flexible fiberscopes in patients with chronic pain. Spine

(Phila Pa 1976) 2003;28:2006–12. doi: 10.1097/01.BRS.0000083595.10862.98. PMID: 12973149.

[50] Berthelot JM, Laredo JD, Darrieutort-Laffite C, Maugars Y. Stretching of roots contributes to the pathophysiology of radiculopathies. Joint Bone Spine 2018;85:41–5. doi: 10.1016/J.JBSPIN.2017.01.004. PMID: 28115269.

[51] Aldrete J A. Nerve root “irritation” or inflammation diagnosed by magnetic resonance imaging. Anesthesiology 2003;98:1294. doi: 10.1097/00000542-200305000-00040. PMID: 12717159.

[52] Villani LA, Digre KB, Cortez MM, Bokat C, Rassner UA, Ozudogru SN. Arachnoiditis, a complication of epidural blood patch for the treatment of low-pressure headache: a case report and systematic review. Headache 2021;61:244–52. doi: 10.1111/head.14076. PMID: 33583044.

[53] Her YF, McWilliams RT, Ovrom EA, Watson JC. Corticosteroid therapy in acute and subacute arachnoiditis – a case series. Int Med Case Rep J 2024;17:235–40. doi: 10.2147/IMCRJ.S445705. PMID: 38559495.

[54] Iqbal IM, Morris R, Hersch M. Adhesive arachnoiditis following inadvertent epidural injection of 2% chlorhexidine in 70% alcohol—partial recovery over the ensuing eight years. Anaesth Intensive Care 2018;46:572–4. doi: 10.1177/0310057X1804600606. PMID: 30447665.

[55] Tseng SH, Lin SM. Surgical treatment of thoracic arachnoiditis with multiple subarachnoid cysts caused by epidural anesthesia. Clin Neurol Neurosurg 1997;99:256–8. doi: 10.1016/S0303-8467(97)00086-3. PMID: 9491300.

[56] Gottschalk A, Schmitz B, Mauer UM, Bornstedt A, Steinhoff S, Danz B, et al. Dynamic visualization of arachnoid adhesions in a patient with idiopathic syringomyelia using high-resolution cine magnetic resonance imaging at 3T. J of Magn Reson Imaging 2010;32:218–22. doi: 10.1002/JMRI.22207. PMID: 20575079.

[57] Hatano K, Ohashi H, Kawamura D, Isoshima A, Nagashima H, Tochigi S, et al. MRI characteristics of syringomyelia associated with foramen magnum arachnoiditis: differentiation from Chiari malformation. Acta Neurochir (Wien) 2021;163:1593–601. doi: 10.1007/S00701-021-04845-9. PMID: 33881607.

[58] Ikushima I, Korogi Y, Hirai T, Yamashita Y. High-resolution constructive interference in a steady state imaging of cervicothoracic adhesive arachnoiditis. J Comput Assist Tomogr 2007;31:143–7. doi: 10.1097/01.RCT.0000230006.46145.16. PMID: 17259847.

[59] Tu YT, Chiang YH, Lin JH. Delta cord as a radiological localization sign of postoperative adhesive arachnoiditis: a case report and literature review. Diagnostics (Basel) 2023;13. doi: 10.3390/DIAGNOSTICS13182942. PMID: 37761311.

[60] Tsuchida R, Sumitani M, Azuma K, Abe H, Hozumi J, Inoue R, et al. A novel technique using magnetic resonance imaging in the supine and prone positions for diagnosing lumbar adhesive arachnoiditis: a preliminary study. Pain Practice 2020;20:34–43. doi : 10.1111/papr.12822. PMID: 31325409.

[61] Warnke JP, Mourgela S. Lumbale adhäsive arachnoiditis. Endoskopische subarachnoepidurostomie als neue behandlungsmöglichkeit [adhesive lumbar arachnoiditis. Endoscopic subarachnoepidurostomy as a new treatment]. Nervenarzt 2007;78:1182–7. doi: 10.1007/s00115-007-2289-x.

[62] Warnke JP, Mourgela S. Endoscopic treatment of lumbar arachnoiditis. Minimally Invasive Neurosurgery 2007;50:1–6. doi: 10.1055/s-2007-970056. PMID: 17546535.

[63] Petrasic JR, Chhabra A, Scott KM. Impact of MR neurography in patients with chronic cauda equina syndrome presenting as chronic pelvic pain and dysfunction. AJNR Am J Neuroradiol 2017;38:418–22. doi: 10.3174/AJNR.A4994. PMID: 28059708.

[64] Hackert J, Maßmann L, Sure U, Forsting M, Kleinschnitz C, Pul R, et al. Immunotherapies in chronic adhesive arachnoiditis - a case series and literature review. ENeurologicalSci 2021;24. doi: 10.1016/j.ensci.2021.100350. PMID: 34195394.

[65] Tennant F, Porcelli M, Guess S. Adhesive arachnoiditis: no longer a rare disease. MedCentral 2020;20.

[66] Gonzalez M. CE, Enriquez LE, Cruz A. C. Arachnoiditis following spinal anesthesia for Cesarean section. Colombian Journal of Anesthesiology 2012;40:150–2. doi: 10.1016/S2256-2087(12)70031-7.

[67] Assey E V., Sadiq AM, Swai MJ, Sadiq AM, Dekker MCJ. Idiopathic arachnoiditis of the cauda equina: a case report from Tanzania. Case Rep Neurol 2021;13:535–40. doi: 10.1159/000518379. PMID: 34720959.

[68] Iwatsuki K, Yoshimine T, Ohnishi YI, Ninomiya K, Moriwaki T, Ohkawa T. Syringomyelia associated with spinal arachnoiditis treated by partial arachnoid dissection and syrinx – far distal subarachnoid shunt. Clin Med Insights: Case Rep 2014;7:107–10. doi: 10.4137/CCRep.S14895. PMID: 25232285.

[69] Mauer UM, Gottschalk A, Kunz U, Schulz C. Arachnoscopy: A special application of spinal intradural endoscopy. Neurosurg Focus 2011;30. doi: 10.3171/2011.1.FOCUS10291. PMID: 21456934.

[70] Peek RD, Thomas JC, Wiltse LL. Diagnosis of lumbar arachnoiditis by myeloscopy. Spine (Phila Pa 1976) 1993;18:2286–9. doi: 10.1097/00007632-199311000-00025. PMID: 8278848.

[71] Kawauchi Y, Yone K, Sakou T. Myeloscopic observation of adhesive arachnoiditis in patients with lumbar spinal canal stenosis. Spinal Cord 1996;34:403–10. doi: 10.1038/SC.1996.72. PMID: 8963995.

[72] Manchikanti L, Abdi S, Atluri S, Benyamin RM, Boswell M V, Buenaventura RM, et al. An update of comprehensive evidence-based guidelines for interventional techniques in chronic spinal pain. Part II: guidance and recommendations. Pain Physician 2013;16:S49–283. doi: 10.36076/ppj.2013/16/S49. PMID: 23615883.

[73] Shinu P, Morsy MA, Nair AB, Mouslem AKA, Venugopala KN, Goyal M, et al. Novel therapies for the treatment of neuropathic pain: potential and pitfalls. J Clin Med 2022;11. doi: 10.3390/jcm11113002. PMID: 35683390.

[74] Day P. Arachnoiditis: A brief summary of the literature. NZHTA Report 2001.

[75] Petty PG, Hudgson P, Hare WSC. Symptomatic lumbar spinal arachnoiditis: Fact or fallacy? Journal of Clinical Neuroscience 2000;7:395–9. doi: 10.1054/jocn.1999.0223. PMID: 10942659.

[76] Li T, Wang Y. A Global bibliometric study of spinal arachnoiditis: research trends and future directions. World Neurosurg 2025;194. doi: 10.1016/j.wneu.2024.123587. PMID: 39710197.

[77] Zuccato M, Shilling D, Fajgenbaum DC. The collaborative network approach: a model for advancing patient-centric research for Castleman disease and other rare diseases. Emerg Top Life Sci 2019;3:97–105. doi: 10.1042/ETLS20180178. PMID: 33523193.

[78] Fajgenbaum DC, Ruth JR, Kelleher D, Rubenstein AH. The collaborative network approach: a new framework to accelerate Castleman's disease and other rare disease research. Lancet Haematol 2016;3:e150–2. doi: 10.1016/S2352-3026(16)00007-7. PMID: 33523193.

[79] Geraci J, Bhargava R, Qorri B, Leonchyk P, Cook D, Cook M, et al. Machine learning hypothesis-generation for patient stratification and target discovery in rare disease: our experience with Open Science in ALS. Front Comput Neurosci 2024;17. doi: 10.3389/fncom.2023.1199736. PMID: 38260713.

[80] ACMCRN. ACMCRN | Empowering arachnoiditis patients through research, advocacy & support 2025. https://www.acmcrn.org/.

[81] Dragan I-M, Isaic-Maniu A. An original solution for completing research through snowball sampling—handicapping method. Adv Appl Sociol 2022;12:729–46. doi: 10.4236/aasoci.2022.1211052.

[82] StuffThatWorks. Introduction & overview | StuffThatWorks | crowdsourcing treatments that work 2024. https://www.stuffthatworks.health/introduction.

[83] Gagne JJ, Thompson L, O'Keefe K, Kesselheim AS. Innovative research methods for studying treatments for rare diseases: Methodological review. BMJ 2014;349. doi: 10.1136/bmj.g6802. PMID: 25422272.

[84] Barak-Levitt J, Held R, Synett Y, Kremer N, Hodak E, Sherman S. Hidradenitis suppurativa international online community: patient characteristics and a novel model of treatment effectiveness. Acta Derm Venereol 2022;102. doi: 10.2340/actadv.v102.1056. PMID: 35312027.

[85] Engel T, Dotan E, Synett Y, Held R, Soffer S, Ben-Horin S, et al. Self-reported treatment effectiveness for Crohn's disease using a novel crowdsourcing web-based platform. United European Gastroenterol J 2023;11:621–32. doi: 10.1002/ueg2.12424. PMID: 37370250.

[86] Held R, Blankstein A. Plantar fasciitis: a novel crowdsourcing approach to data collection and analysis. J Musculoskelet Res 2021;24. doi: 10.1142/S0218957721500238.

[87] Vears D, Gillam L. Inductive content analysis: A guide for beginning qualitative researchers 2022;23. doi: 10.11157/fohpe.v23i1.544.

[88] Innovation and Value Initiative, EveryLife Foundation for rare disease. Valuing rare disease treatments in healthcare: Real Experience, Real Impact. 2024.

[89] McQueen RB, Mendola ND, Jakab I, Bennett J, Nair K V., Németh B, et al. Framework for patient experience value elements in rare disease: a case study demonstrating the applicability of combined qualitative and quantitative methods. Pharmacoecon Open 2023;7:217–28. doi: 10.1007/s41669-022-00376-w. PMID: 36316575.

[90] Fairweather D, Beetler DJ, McCabe EJ, Lieberman SM. Mechanisms underlying sex differences in autoimmunity. Journal of Clinical Investigation 2024;134:e180076. doi: 10.1172/JCI180076. PMID: 39286970.

[91] Coyle PK. What can we learn from sex differences in MS? J Pers Med 2021;11. doi: 10.3390/jpm11101006. PMID: 34683148.

[92] Aldrete JA. Chronic adhesive arachnoiditis. Br J Anaesth 2004;93:301–3. doi: 10.1093/bja/aeh591. PMID: 15251994.

[93] Fagundes W, Zottele MZ, Cavalcanti M, Silva YP. Neurosurgical challenges in recurrent adhesive arachnoiditis after spinal anesthesia for Cesarean delivery: case report and literature review. Cureus 2025;17:e86379. doi: 10.7759/CUREUS.86379. PMID: 40688970.

[94] Silva M, Halpern SH. Epidural analgesia for labor: current techniques. Local Reg Anesth 2010;3:143–53. doi: 10.2147/LRA.S10237. PMID: 23144567.

[95] Cesare N, Grant C, Nsoesie EO. Understanding demographic bias and representation in social media health data. WebSci 2019 - companion of the 11th ACM Conference on Web Science, Association for Computing Machinery; 2019, p. 7–9. doi: 10.1145/3328413.3328415.

[96] Whitaker C, Stevelink S, Fear N. The use of Facebook in recruiting participants for health research purposes: a systematic review. J Med Internet Res 2017;19:e290. doi: 10.2196/jmir.7071. PMID: 28851679.

[97] Shumway NK, Cole E, Fernandez KH. Neurocutaneous disease: Neurocutaneous dysesthesias. J Am Acad Dermatol 2016;74:215–28. doi: 10.1016/j.jaad.2015.04.059. PMID: 26775772.

[98] Yamada S, Lonser RR, Colohan AR, Yamada CT. Tethered cord syndrome in adult and late-teenage patients without neural spinal dysraphism. In: Yamada S, editor. Tethered cord syndrome in children and adults. 2nd ed, Stuttgart: Georg Thieme Verlag KG; 2010, p. 162–79. doi: 10.1055/b-002-80413.

[99] Phi JH, Lee DY, Jahng TA, Chung CK, Kim HJ. Tethered cord syndrome in adulthood: reconsidering the prognosis. J Korean Neurosurg Soc 2004;36:114–9.

[100] Oz O, Ulas U, Duz B, Yücel Mehmet, Odabasi Z. Electrophysiological findings in patients with adult tethered cord syndrome. Turk Neurosurg 2010;20:16–20.

[101] Nogués MA, Stålberg E. Electrodiagnostic findings in syringomyelia. Muscle Nerve 1999;22:1653–9.

[102] Hulens M, Bruyninckx F, Dankaerts W, Vansant G, De Mulder PA. Electromyographic abnormalities associated with symptomatic sacral Tarlov cysts. Pain Practice 2016;16:E81–8. doi: 10.1111/papr.12441. PMID: 26952047.

[103] Hulens M, Bruyninckx F, Somers A, Stalmans I, Peersman B, Greet V, et al. Electromyography and a review of the literature provide insights into the role of sacral perineural cysts in unexplained chronic pelvic, perineal and leg pain syndromes. Int J Phys Med Rehabil 2017;5. doi: 10.4172/2329-9096.1000407.

[104] Luthra K, Darwish Y, Ritter S, Gopal N, Benkovic S, Suri P, et al. Intercepting Intracept: A case report of idiopathic arachnoiditis. J Rehab and Pain Med 2023;1:168–75. doi: 10.37191/mapsci-jrpm-1(3)-018.

[105] Cornelson SM, Johnnie ED, Kettner NW. Neural mobilization in a 54-year-old woman with postoperative spinal adhesive arachnoiditis. J Chiropr Med 2018;17:283–8. doi: 10.1016/J.JCM.2018.07.004. PMID: 30846922.

[106] Ospelnikova TP, Shitova AD, Voskresenskaya ON, Ermilova E V. Neuroinflammation in the pathogenesis of neuropathic pain syndrome. Neurosci Behav Physiol 2023;53:27–33. doi: 10.1007/S11055-023-01387-8/METRICS.

[107] Yamada S, Won DJ, Pezeshkpour G, Yamada BS, Yamada SM, Siddiqi J, et al. Pathophysiology of tethered cord syndrome and similar complex disorders. Neurosurg Focus 2007;23:E6. doi: 10.3171/FOC-07/08/E6. PMID: 17961011.

[108] Shih P, Halpin RJ, Ganju A, Liu JC, Koski TR. Management of recurrent adult tethered cord syndrome. Neurosurg Focus 2010;29:1–5. doi: 10.3171/2010.3.FOCUS1073. PMID: 20594003.

[109] Hodges PW, Gandevia SC. Changes in intra-abdominal pressure during postural and respiratory activation of the human diaphragm. J Appl Physiol 2000;89:967–76. doi: 10.1152/JAPPL.2000.89.3.967. PMID: 10956340.

[110] Aktas G, Kollmeier JM, Joseph AA, Merboldt KD, Ludwig HC, Gärtner J, et al. Spinal CSF flow in response to forced thoracic and abdominal respiration. Fluids Barriers CNS 2019;16. doi: 10.1186/S12987-019-0130-0. PMID: 30947716.

[111] Zhang Z, Wang X, Jonas JB, Wang H, Zhang X, Peng X, et al. Valsalva manoeuver, intra-ocular pressure, cerebrospinal fluid pressure, optic disc topography: Beijing intracranial and intra-ocular pressure study. Acta Ophthalmol 2014;92:e475-80. doi: 10.1111/AOS.12263. PMID: 24020862.

[112] Depauw PRAM, Groen RJM, Van Loon J, Peul WC, Malbrain MLNG, De Waele JJ. The significance of intra-abdominal pressure in neurosurgery and neurological diseases: A narrative review and a conceptual proposal. Acta Neurochir (Wien) 2019;161:855–64. doi : 10.1007/S00701-019-03868-7. PMID: 30911831.

[113] Lloyd RA, Butler JE, Gandevia SC, Ball IK, Toson B, Stoodley MA, et al. Respiratory cerebrospinal fluid flow is driven by the thoracic and lumbar spinal pressures. J Physiol 2020;598:5789–805. doi: 10.1113/JP279458. PMID: 32990956.

[114] Heiss JD, Snyder K, Peterson MM, Patronas NJ, Butman JA, Smith RK, et al. Pathophysiology of primary spinal syringomyelia. J Neurosurg Spine 2012;17:367–80. doi: 10.3171/2012.8.SPINE111059. PMID: 22958075.

[115] Geneen LJ, Moore RA, Clarke C, Martin D, Colvin LA, Smith BH. Physical activity and exercise for chronic pain in adults: An overview of Cochrane Reviews. Cochrane Database Syst Rev 2017;1. doi: 10.1002/14651858.CD011279.PUB2. PMID: 28087891.

[116] Grooten WJA, Boström C, Dedering Å, Halvorsen M, Kuster RP, Nilsson-Wikmar L, et al. Summarizing the effects of different exercise types in chronic low back pain – a systematic review of systematic reviews. BMC Musculoskelet Disord 2022;23:49. doi: 10.1186/S12891-022-05722-X/TABLES/21. PMID: 35996124.

[117] Lima L V., Abner TSS, Sluka KA. Does exercise increase or decrease pain? Central mechanisms underlying these two phenomena. J Physiol 2017;595:4141–50. doi: 10.1113/JP273355. PMID: 28369946.

[118] Leitzelar BN, Koltyn KF. Exercise and neuropathic pain: a general overview of preclinical and clinical research. Sports Med Open 2021;7. doi: 10.1186/S40798-021-00307-9. PMID: 33751253.

[119] Jackson A, Isherwood I. Does degenerative disease of the lumbar spine cause arachnoiditis? A magnetic resonance study and review of the literature. British Journal of Radiology 1994;67:840–7. doi: 10.1259/0007-1285-67-801-840. PMID: 7953223.

[120] Epstein JA, Epstein BS, Lavine LS, Rosenthal AD, Decker RE, Carras R. Obliterative arachnoiditis complicating lumbar spinal stenosis. J Neurosurg 1978;48:252–8. doi: 10.3171/JNS.1978.48.2.0252. PMID: 624974.

[121] Cancino GG, López-Valdés JC, Valdez-Rodríguez A, Loreto-Lucas M, Vega-Moreno DA, Betancourt-Quiroz C, et al. Predisposing factors for failed back surgery syndrome following lumbar instrumentation: retrospective study. Cirugía de Columna 2025;3:253–9. doi: 10.35366/120969.

[122] Ahn M-W, Kim Y-Y, Byun W-M. The arachnoiditis-like nerve root distribution in the thecal sac of the degenerative disc diseases. J Korean Soc Spine Surg 1997;4:300–8. doi: 10.4184/jkss.1997.4.2.300.

[123] Klepinowski T, Orbik W, Sagan L. Global incidence of spinal perineural Tarlov's cysts and their morphological characteristics: a meta-analysis of 13,266 subjects. Surgical and Radiologic Anatomy 2021;43:855–63. doi: 10.1007/s00276-020-02644-y. PMID: 33452905.

[124] Carroll MB. Hypermobility spectrum disorders: A review. Rheumatol Immunol Res 2023;4:60–8. doi : 10.2478/rir-2023-0010. PMID: 37637226.

[125] Henderson FC, Austin C, Benzel E, Bolognese P, Ellenbogen R, Francomano CA, et al. Neurological and spinal manifestations of the Ehlers–Danlos syndromes. Am J Med Genet C Semin Med Genet 2017;175:195–211. doi: 10.1002/AJMG.C.31549. PMID: 28220607.

[126] Fitzcharles MA, Perrot S, Häuser W. Comorbid fibromyalgia: A qualitative review of prevalence and importance. Eur J Pain 2018;22:1565–76. doi: 10.1002/EJP.1252. PMID: 29802812.

[127] Wawrzyniak A, Lubiatowski P. Shoulder arthropathy secondary to syringomyelia: systematic review. EFORT Open Rev 2023;8:26–34. doi: 10.1530/EOR-22-0008. PMID: 36705617.

[128] Henke AM, Billington ZJ, Gater DR. Autonomic dysfunction and management after spinal cord injury: a narrative review. J Pers Med 2022;12. doi: 10.3390/JPM12071110. PMID: 35887607.

[129] Muro K, DiPatri Jr. AJ, McLone DG. The Cervical Tethered Spinal Cord. In: Yamada S, editor. Tethered Cord Syndrome in Children and Adults. Second, Stuttgart: Georg Thieme Verlag KG; 2010, p. 102–9. doi: 10.1055/b-002-80413.

[130] Her YF. A proposed multimodal therapy approach for the treatment of arachnoiditis. J Clin Med Case Stud 2024;9. doi: 10.4172/JClinMedCaseStud.9.2.001.

[131] Jha S. Algorithms at the gate - radiology's AI adoption dilemma. JAMA 2023;330:1615–6. doi: 10.1001/jama.2023.16049. PMID: 37801311.

[132] Bock A, Hswen Y. How artificial intelligence will enhance imaging access and analysis. JAMA 2024;331:1979–81. doi 10.1001/jama.2024.7251. PMID: 38787567.

[133] Wangberg SC, Andreassen HK, Prokosch HU, Santana SMV, Sørensen T, Chronaki CE. Relations between internet use, socio-economic status (SES), social support and subjective health. Health Promot Int 2008;23:70–7. doi: 10.1093/HEAPRO/DAM039. PMID: 18083686.

[134] Hasebrink U, Jensen KB, Bulck H Van Den, Hölig S, Maeseele P. Media audiences |changing patterns of media use across cultures: a challenge for longitudinal research. Int J Commun 2015;9:435–57.

[135] Faye F, Crocione C, Anido de Peña R, Bellagambi S, Escati Peñaloza L, Hunter A, et al. Time to diagnosis and determinants of diagnostic delays of people living with a rare disease: results of a Rare Barometer retrospective patient survey. European Journal of Human Genetics 2024;32:1116–26. doi: 10.1038/s41431-024-01604-z. PMID: 38755315.

[136] Baxter MF, Hansen M, Gration D, Groza T, Baynam G. Surfacing undiagnosed disease: consideration, counting and coding. Front Pediatr 2023;11. doi: 10.3389/fped.2023.1283880. PMID: 38027298.

[137] Ng IK, Tham SZ, Singh GD, Thong C, Teo DB. Medical gaslighting: a new colloquialism. American Journal of Medicine 2024;137:920–2. doi: 10.1016/j.amjmed.2024.06.022. PMID: 38936758.

[138] Shapiro D, Hayburn A. Medical gaslighting as a mechanism for medical trauma: case studies and analysis. Curr Psychol 2024;43:34747–60. doi: 10.1007/S12144-024-06935-0/TABLES/1.

[139] Halverson CME, Penwell HL, Francomano CA. Clinician-associated traumatization from difficult medical encounters: Results from a qualitative interview study on the

Ehlers-Danlos Syndromes. SSM - Qualitative Research in Health 2023;3:100237. doi: 10.1016/J.SSMQR.2023.100237. PMID: 37426705.

[140] Rust R, Yin H, Buil BA, Sagare AP, Kisler K. The blood-brain barrier: a help and a hindrance. Brain 2025. doi: 10.1093/BRAIN/AWAF068. PMID: 39969549.

[141] Feigenbaum F, Parks SE, Chapple KM. Prospective validation of a quality-of-life measure for women undergoing surgical intervention for symptomatic sacral Tarlov cysts: the Tarlov cyst quality of life scale. World Neurosurg 2022;165:e276–81. doi: 10.1016/J.WNEU.2022.06.033. PMID: 35700862.

Supporting information

S1 File (PDF): Survey questions used in data collection.

Selected StuffThatWorks (STW) survey questions used in data collection.

S1 Table (XLXS): Symptoms reported by ≥ 1% of the study population.

Full list of symptoms reported by ≥ 1% of the total study population ordered by frequency (n, % and score).

S2 Table (XLXS): Early symptoms reported by ≥ 1% of the study population.

Full list of early symptoms reported by ≥ 1% of the total study population ordered by frequency (n, % and score).

S3 Table (XLXS): Aggravating factors reported by ≥ 1% of the study population.

Full list of aggravating factors reported by ≥ 1% of the total study population ordered by frequency (n, % and score).